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ABSTRACT 
Eliza Mason: Virulence gene regulation in Bordetella 
(Under the direction of Peggy A. Cotter) 
 
Bordetella species cause respiratory infections in mammals. Their master regulatory 
system BvgAS controls expression of at least three distinct phenotypic phases in response to 
environmental cues. The Bvg+ phase is necessary and sufficient for respiratory infection 
while the Bvg– phase is required for survival ex vivo. We developed a plasmid, pGFLIP, that 
encodes a sensitive Flp recombinase-based fluorescent reporter system able to document 
gene activation both in vitro and in vivo. Using pGFLIP, we demonstrated that cyaA, 
considered to be a “late” Bvg+ phase gene, is activated substantially earlier in B. 
bronchiseptica compared to B. pertussis following a switch from Bvg– to Bvg+ phase 
conditions. We show that the altered activation of cyaA is not due to differences in the cyaA 
promoter or in the bvgAS alleles of B. bronchiseptica compared to B. pertussis, but appears to 
be species-specific. Finally, we used pGFLIP to show that flaA remains repressed during 
infection, confirming that wild-type B. bronchiseptica do not modulate to the Bvg– phase in 
vivo. Additionally, we obtained large colony variants (LCVs) from the lungs of mice infected 
with B. bronchiseptica strain RBX9, which contains an in-frame deletion mutation in fhaB, 
encoding filamentous hemagglutinin. RBX9 also yielded LCVs when switched from Bvg–
 phase conditions to Bvg+ phase conditions in vitro. We determined that LCVs are composed 
of both Bvg+ and Bvg– phase bacteria and that they result from defective bvgAS positive 
autoregulation. The LCV phenotype was linked to the presence of a divergent promoter 5′ 
iii 
to bvgAS, suggesting a previously undescribed mechanism of transcriptional interference 
that, in this case, leads to feedback-based multistability (FBM). Our results also indicate that 
a small proportion of RBX9 bacteria modulates to the Bvg– phase in vivo. In addition to 
providing insight into transcriptional interference and FBM, our data provide an example of 
an in-frame deletion mutation exerting a ‘polar’ effect on nearby genes. 
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CHAPTER 1: Introduction 
 
The goal of this dissertation was to explore Bordetella virulence gene regulation. 
Throughout this process we developed new and sensitive tools to detect gene activation as 
well as characterized an interesting colony morphotype. These projects were intimately 
related to understanding the Bordetella master regulatory system, BvgAS. However, the 
insight these projects have provided should be widely relevant to understanding other Gram-
negative pathogens and bacterial transcription processes in general.  
The Bordetella genus currently comprises nine species of Gram-negative bacteria, 
several of which are human-and animal-adapted pathogens. The so-called classical 
Bordetella species have been well-characterized and include extracellular respiratory 
pathogens B. pertussis, B. parapertussisHu, and B. bronchiseptica (1–3). The obligate human 
pathogens B. pertussis and B. parapertussisHu cause the disease whooping cough, an acute 
respiratory illness that has a high mortality rate in infants (4, 5). B. bronchiseptica naturally 
infects a wide-range of mammals, including canines, livestock, and occasionally humans and 
generally causes a more chronic, asymptomatic infection (6, 7). Outside of the host, B. 
bronchiseptica is thought to inhabit environmental reservoirs, although none so far have been 
identified (6). The bird pathogen B. avium infects poultry and causes rhinotracheitis and 
coryza (2, 8). Only one species, B. petrii, has been isolated from the environment (9, 10). 
The remaining Bordetella species were discovered from various human clinical isolates, 
although their pathogenic potential remains unclear (9).
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Historically, B. pertussis was a serious public health threat. Before vaccines were 
developed, whooping cough was a leading cause of infant death worldwide, causing almost 
200,000 cases per year in the United States alone (http://www.cdc.gov/pertussis/surv-
reporting/cases-by-year.html). Initially, a whole-cell vaccine (which consisted of killed B. 
pertussis organisms) was developed, and as a result, cases of whooping cough dramatically 
decreased (11). Although the whole cell vaccine was extremely successful in providing 
protection against infection, reports of severe neurological side effects cast doubt upon its 
safety (12). About two decades ago, a less reactogenic acellular vaccine, consisting of a 
cocktail of purified B. pertussis virulence factors, was deployed. This acellular vaccine was 
purported to be much safer, but just as effective, as the whole cell vaccine. These acellular 
vaccines are now the international standard for pertussis vaccination (13). Interestingly, 
however, the incidence of pertussis has gradually increased since the introduction of the 
acellular vaccine (14). In addition, the US has recently experienced several outbreaks, 
including one in California and an epidemic in Washington State (15, 16). Despite continuing 
efforts, the bordetellae continue to present problems not only for humans, but for 
domesticated animals as well, imparting significant economic losses (17). These trends 
demonstrate the importance of the continual investigation of Bordetella and provide an 
impetus for improving current vaccines. 
Several Bordetella genomes have been fully sequenced and annotated, revealing their 
evolutionary relationships. Sequence data confirmed that B. pertussis, B. parapertussis, and 
B. bronchiseptica are extremely closely related, despite their diverse hosts (18). Additionally, 
phylogenetic analyses revealed that B. pertussis and B. parapertussis have recently (~3 
m.y.a.) evolved from a B. bronchiseptica-like ancestor (19). Therefore, these species are 
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often regarded as subspecies and together encompass the B. bronchiseptica cluster. Research 
in the Bordetella field has been primarily focused on these pathogens. 
Interesting clues about the evolution of Bordetella virulence have emerged from 
subsequent genome-wide studies. For example, all Bordetella are proposed to have evolved 
from a primitive B. petrii-like ancestor (hypothesized to be non-pathogenic) (9, 10). 
Coincidently, B. petrii and B. bronchiseptica (the evolutionarily ancestral species) have the 
largest genomes, containing over five mega-bases (Mb) and more than five thousand genes 
(10, 18). These large genomes likely encode a versatile repertoire of proteins that enable 
survival in diverse environments. In contrast, B. pertussis, and to a lesser extent, B. 
parapertussisHu, have considerably smaller genomes (~4 Mbp and 4.8 Mbp, respectively) and 
encode significantly fewer proteins. Remarkably, this massive loss of genetic information 
resulted in increased disease severity and narrowed host specificity. In many cases, virulence 
emerged with the acquisition of new genes, such as in Salmonella and Vibrio spp. (20). For 
B. pertussis, reductive evolution was strongly influenced by substantial genomic 
rearrangements, invasion of mobile elements, and rampant recombination (18). These events 
led to an increase in the frequency of pseudogenes and large genomic deletions, somehow 
allowing this organism to specialize in the human host. Despite the dramatic differences in 
genome size, the presence and regulation of virulence genes is highly conserved among the 
Bordetella. 
The regulation of all known virulence factor genes in Bordetella has been attributed 
to a single two-component regulatory system, BvgAS, where BvgS is a sensor kinase and 
BvgA is a response regulator transcription factor (Figure 1) (21–24). Bacteria deficient for 
BvgAS are completely innocuous and cannot establish an infection (25). Homologues of 
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bvgAS have been found in all Bordetella species (9), supporting the hypothesis that BvgAS 
represents an ancestral system that was not initially dedicated to virulence. In the B. 
bronchiseptica cluster, BvgAS and its contribution to pathogenesis have been well 
characterized. BvgAS is a global regulator that controls hundreds of genes and at least three 
distinct phenotypic phases, including the Bvg+, Bvgi, and Bvg– phases, in response to 
environmental signals (23). By investigating of the evolution of BvgAS and its regulon, we 
hope to understand differences in host specificity and disease severity between these species. 
Although specific genes that determine the host ranges of these pathogens have not 
been found, a few species-specific patterns of regulation have been identified. While it is true 
that, among the B. bronchiseptica cluster, BvgAS and most of the virulence factors have 
remained conserved (i.e., the virulence factors filamentous hemaglutinnin , adenylate cyclase 
toxin, pertactin, and BipA share over 90% amino acid sequence identity), a number of 
mutations have confered altered patterns of regulation. For example, several genes that are 
not BvgAS-regulated in B. bronchiseptica have evolved to come under control of BvgAS in 
B. pertussis, and vice versa. One of the most characterized and highly expressed set of toxin 
genes in B. pertussis, ptxA-E (encoding the AB5-type pertussis toxin), is not under BvgAS 
control in B. bronchiseptica (26). The Type III secretion system, which secretes only one 
known highly-cytopathic effector, BteA, is encoded by genes positively regulated by BvgA, 
but whose products are only secreted in B. bronchiseptica (27). Another gene that has 
remained conserved but is differentially expressed in B. bronchiseptica and B. pertussis is 
batB, which encodes an autotransporter involved in binding antibodies during B. 
bronchiseptica infection (28). Together, these genes have been maintained in Bordetella, yet 
have been reprogrammed to become active under different conditions. Although little is 
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understood about why the regulation has changed, it is likely that these changes represent 
examples of adaptation to species-specific niches. 
In addition, although the BvgAS- (or virulence) activated genes (vags) are generally 
conserved among Bordetella species, the BvgAS- (virulence) repressed genes (vrgs) are quite 
diverse (1). Gene inactivation events in B. pertussis eliminated several vrg loci present in B. 
bronchiseptica, including those required for motility and chemotaxis, (which apparently 
became unnecessary in the human host) (18, 29). However, B. pertussis also expresses 
unique vrgs that encode outer membrane proteins of unknown function (30). In B. 
bronchiseptica, data suggest that the Bvg– and Bvgi phases increase fitness in nutrient-
limiting conditions (i.e., ex vivo); however, the role of these phases in B. pertussis remains 
unclear (31, 32). 
 
Figure 1. BvgAS controls least four classes of gene expression and three phenotypic 
phases in response to environmental stimuli; A, BvgAS controls the Bvg, Bvgi, and Bvg+ 
phases and is repressed by chemical modulators or low temperatures; B, The three 
phenotypic phases are defined by unique patterns of gene expression and rely on the 
intracellular concentration of BvgA~phosphate (BvgA~P); C, The chromosomal 
organization of the fhaB and bvgAS loci, including promoters that drive each gene (see 
text for details). 
 
The Bvg+, Bvgi, and Bvg– phenotypic phases were first described by Leslie and 
Gardner in the 1930s and 1940s and then further characterized by Lacey in 1960 (33, 34). 
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Since then, much has been learned about BvgAS and the regulation of these phases. 
Bordetella can freely transition between each state given the appropriate environmental 
signals that activate or inactivate BvgAS. Although the natural signals that BvgAS responds 
to are unknown, several laboratory conditions have been identified that manipulate its 
activity (Figure 1A). Growth on Bordet-Gengou (BG) blood agar plates or in Stainer-Scholte 
(SS) medium at 37˚C confers the Bvg+ phase phenotype, in which BvgAS is abundant and 
highly active (35). With the addition of millimolar concentrations of nicotinic acid or 
magnesium sulfate to the growth media, or growth at lower temperature (30˚C), BvgAS 
activity is inhibited and bacteria convert to the Bvg– phase (this transition is subsequently 
referred to as BvgAS modulation) (23). Addition of an intermediate concentration of 
chemical modulators induces the Bvgi phase (23, 32). 
Each phenotypic state can easily be distinguished by the physical characteristics 
exhibited during colony growth. For example, in the Bvg+ phase, bacteria form colonies that 
are small, domed, and hemolytic on BG blood agar (34). In contrast, bacteria in the Bvg– 
phase form colonies that are large, flat, and non-hemolytic when grown on BG blood agar + 
50 mM MgSO4 (34). Likewise, bacteria in the Bvgi phase exhibit features intermediate to the 
Bvg+ and Bvg– phases, both in terms of colony size and hemolysis (32). 
Each BvgAS-regulated phenotype is determined by unique patterns of gene 
expression. After several years of research, many details of transcriptional regulation have 
emerged. So far, four classes of BvgAS-regulated genes have been characterized, based on 
the location and affinity of BvgA binding sites at their promoter regions (Figure 1B) (23, 36–
39). Because each phenotypic state can be induced both by steady-state environments as well 
as in a temporal manner upon change in environment, gene classes are also categorized based 
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on when they are expressed maximally. Class 1 (late Bvg+ phase) genes include cyaA and 
ptxA (both Class 1 in B. pertussis only) (40). These genes are activated relatively late under 
Bvg+ phase conditions and have multiple low affinity BvgA binding sites within their 
promoters (40). Cooperative binding of BvgA at low affinity sites permits activation only 
after a certain concentration of BvgA is achieved. In contrast, Class 2 (early Bvg+ genes), 
including fhaB and bvgAS itself, have several high affinity BvgA binding sites in their 
promoters and are thus activated immediately upon the Bvg+ phase transition (23). There is 
only one characterized Class 3 (Bvgi phase) gene, bipA. Interestingly, this gene contains both 
high affinity BvgA binding sites, located upstream from its transcription start site, and low 
affinity BvgA binding sites, located downstream from its translational start site (41). When 
BvgA levels increase during the transition to Bvg+ phase, bipA is immediately transcribed 
due to the high affinity binding sites. However, once BvgA levels reach a certain threshold, 
bipA is repressed due to the physical inhibition of RNA polymerase (RNAP) by BvgA~P 
bound at the low affinity sites (41). Lastly, Class 4 (Bvg– phase) genes are vrgs such as flaA 
and frlAB (in B. bronchiseptica only); these genes are repressed (directly or indirectly) by 
BvgA (23). Despite the large amount of work that has been done to characterize each gene 
class, only a few genes have been actually classified. Additionally, the majority of vrgs 
remain grossly under-investigated, primarily because no role during infection has been 
established.  
Like all two-component systems, BvgAS relies on a phosphorelay to convey signal 
activation. Upon sensing activating signals (Bvg+ phase environments) in the periplasm, 
BvgS autophosphorylates and delivers this phosphate group forward through three 
subdomains (the transmitter, receiver, and histidine phosphotransfer-domain) and finally to 
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an aspartate residue in BvgA (21). When BvgA is converted into BvgA~P, it dimerizes and 
gains high affinity for specific DNA sequences (42). BvgA~P then activates or represses 
transcription by binding to promoter regions (37). Because bvgAS is positively autoregulated, 
the total concentration of BvgAS as well as BvgA~P gradually increases to a maximum when 
bacteria sense sustained Bvg+ phase signals (43, 44). These observations have culminated in 
the hypothesis that the phenotypic phase of each bacterium is determined by the intracellular 
concentration of BvgA~P; in the Bvg– phase, the concentration of BvgA~P is minimal, in the 
Bvgi phase, the concentration of BvgA~P is intermediary, and in the Bvg+ phase, BvgA~P is 
maximal. This hypothesis has been strongly supported by recent experiments that determined 
BvgA and BvgA~P levels within bacterial cultures under modulating and non-modulating 
conditions (45).  
All evidence thus far supports the following series of events during the transition 
between phases. In the Bvg– phase (where BvgAS-activating signals are absent – or BvgAS-
inactivating signals are present), there is a low basal concentration of BvgA (and little to no 
BvgA~P), leading to activation of Bvg– phase genes in the absence of BvgA~P-mediated 
repression. When switched to Bvg+ phase conditions, the basal amount of BvgA is 
phosphorylated, leading to the activation of early Bvg+ phase genes (including, importantly, 
bvgAS itself) and Bvgi phase genes, which require a relatively low concentration of BvgA~P, 
as well as repression of the Bvg– phase genes. Due to positive autoregulation, levels of BvgA 
increase with a concomitant increase in BvgA~P until the cellular concentration reaches that 
required to activate the late Bvg+ phase genes. Cells remain in the Bvg+ phase until BvgAS 
receives a repressive signal. Transition back to the Bvg– phase requires that BvgA~P levels 
decrease to the minimum level and probably occurs through phosphatase activity of BvgS on 
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BvgA~P as well as through natural hydrolysis of the phosphoryl group from BvgA~P. In this 
manner, BvgAS precisely controls the physiological state of each cell. 
Critical to the transition to the Bvg+ phase, positive autoregulation of bvgAS was 
discovered around 1990 and later characterized by Williams et al. in 2007 (25, 43, 44, 46). In 
the B. bronchiseptica cluster, bvgAS lies adjacent to fhaB and is transcribed divergently 
(Figure 1C). The 426bp region between these genes contains at least three promoters: two 
that drive bvgAS and one that drives fhaB (25). Because both of these genes respond to 
BvgAS, there are also multiple BvgA binding sites associated with these promoters; 
therefore, it is likely that this entire region is completely occupied under Bvg+ phase 
conditions due to cooperative binding of BvgA~P (47). The two promoters that regulate 
bvgAS are called P2 (which is constitutively active at low levels) and P1 (which is activated 
by BvgA~P) and control the transcription of bvgAS under modulating and non-modulating 
conditions, respectively (25). Therefore, under Bvg– phase conditions, P2 is active and 
responsible for the low, basal concentration of BvgA within the cell. Upon transition to the 
Bvg+ phase, the basal level of BvgA is converted to BvgA~P, which is sufficient to activate 
transcription at P1, as well as at other early and intermediate Bvg+ phase promoters, including 
PfhaB (23). Enhanced and sustained transcription at P1 increases the concentration of BvgA 
such that, eventually (as BvgA is quickly converted to BvgA~P), the late Bvg+ phase genes 
such as ptxA and cyaA (B. pertussis only) are transcribed (23, 40). Interestingly, Williams et 
al. demonstrated that by replacing the entire bvgAS promoter region with a constitutively 
high or constitutively low promoter (and thus removing autoregulation), the maintenance of 
and transition between phases could be altered (44). Because a constitutive promoter dictates 
a constant and specific level of BvgA (which is still converted into BvgA~P upon sensing 
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activating conditions), both the high and low constitutive mutants could achieve the Bvg– 
phase state (where BvgA~P is minimal), but the amount of time required to transition and the 
ability to transition to the Bvg+ phase was altered (44). Notably, when bvgAS transcription 
was driven by the constitutively low active promoter, bacteria could transition to only the 
Bvgi phase when exposed to Bvg+ phase conditions, providing strong evidence that the Bvgi 
phase is induced by relatively low levels of BvgA~P while much higher levels are required to 
induce the Bvg+ phase.  
Data obtained thus far indicate that the Bvg+ phase is necessary and sufficient to 
cause respiratory infection, the Bvg– phase facilitates ex vivo survival (B. bronchisetpica 
only), and modulation to the Bvgi or Bvg– phase does not occur during infection (31, 48–52). 
For example, Bvg+ phase-locked bacteria behave identically to wild-type bacteria in 
colonization, persistence, and contribution to lung pathology (31, 48, 49, 52). In contrast, 
Bvg– phase-locked bacteria are rapidly cleared from the host, and Bvgi phase-locked bacteria 
have severe defects in colonization and persistence (31, 48–52). Additionally, flaA is not 
expressed at a detectable level when mice are infected with the B. bronchiseptica wild-type 
strain RB50 (40) and the ectopic production of flagella in the Bvg+ phase is actually 
detrimental to infection (48). Although the natural signals that affect BvgAS activity and the 
biological relevance of modulation remain unknown, all data suggest that wild-type 
Bordetella do not modulate to the Bvg– phase within the mammalian host. 
The murine lung inflammation model has been popular for studying Bordetella 
pathogenesis (50, 53–57). This model has been used to characterize the roles of several 
virulence factors in B. bronchiseptica and B. pertussis. At least for B. pertussis, however, the 
mouse model is quite limited: mice are not natural hosts of B. pertussis, they do not mimic 
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human disease progression when infected, and “infection” requires enormous numbers of 
bacteria to be delivered directly to the lungs. Recently, a baboon model of B. pertussis 
infection has been developed (58). Preliminary studies appear very promising; infected 
baboons demonstrate both human-like symptoms and disease transmission (59–61). Several 
studies are underway to increase our understanding of Bordetella pathogenesis and vaccine 
efficacy using this model.  
Studies using B. bronchiseptica and natural animal hosts have been particularly useful 
in characterizing specific virulence factors. Because B. bronchiseptica naturally infects a 
wide range of mammals, several natural host animal models are available, including mice, 
rabbits, rats, and swine. Additionally, B. bronchiseptica rarely infects humans, grows faster 
under laboratory conditions, and is more genetically tractable than B. pertussis. The fact that 
many virulence factors are interchangeable within the B. bronchiseptica cluster also allows 
the study of their function regardless of species (53, 62, 63).  
Filamentous hemagglutinin (FHA) is regarded as one of the most important virulence 
factors of Bordetella and is a primary component of the acellular vaccine (1, 13, 64). FHA is 
a prototypical member of the Two-Partner Secretion (TPS) pathway (a subcategory of Type 
V Secretion), is both cell-associated and secreted, and was first characterized as an adhesin 
(64–66). In addition to mediating adherence to host cells, FHA mediates immunosuppression 
during infection, and acts in concert with other virulence factors to subvert host innate 
immunity (63, 67).  
FHA function is directly dependent on its proper secretion, folding, and presentation 
on the cell surface (66, 68). This is accomplished efficiently through the TPS pathway, which 
is widespread in Gram-negative bacteria and is often associated with virulence (69–71). In 
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general, all TPS systems contain at least two components: a large TpsA exoprotein, and a 
TpsB β-barrel pore protein responsible for translocating the TpsA protein through the outer 
membrane (70). Once translated, TpsA proteins are directed through the inner membrane by 
the general secretory system Sec (70). The TpsA protein is then exported from the periplasm 
to the surface through the TpsB pore, although the energy source for this secretion step is 
unknown. Several conserved domains exist within TpsA proteins, all of which FHA 
possesses (Figure 2A) (71). For example, many TpsA proteins (and autotransporters) contain 
a signal pepide with an N-terminal extension. This signal peptide extension has been 
proposed to direct later steps in protein biogenesis and translocation, although these 
phenotypes are often subtle (72–74). Additionally, a TPS domain, which is found C-terminal 
to the signal peptide, is responsible for interacting with and recognizing sequences in the 
TpsB pore (70). TpsA proteins also frequently contain a structurally conserved β-helical shaft 
which can consist of loosely conserved repeats (75, 76) Lastly, a functional domain is often 
found at the distal terminus, providing adhesive or cytopathic functions.  
FHA is an unusually large protein; it is initially translated as a ~370kD 
“preproprotein” which is then cleaved by the signal peptidase, and is additionally processed 
to several “mature” ~240kD forms by the surface-associated protease SphB1 and an as of yet 
unidentified periplasmic protease during secretion (Figure 2B) (66). FHA’s unwieldy size is 
complemented by its extended conformation; it has a long stalk-like β-helical domain that 
terminates in the globular Mature C-terminal Domain (MCD). This protein is almost 50nm 
long in its secreted form (77) and it is hypothesized that this length is required to span across 
the extracellular region so that the functional domain, the MCD (66), can interact with host 
cells. 
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Figure 2. A, Schematic of the fhaB gene and its product, FhaB, including the domains 
Signal Sequence (SS) (yellow), Two-Partner Secretion domain (TPS) (red), β-helical 
shaft (blue), Mature C-Terminal Domain (MCD) (green), and prodomain (orange); B, 
schematic of the mature FHA tertiary structure; C, Simplified model of FhaB secretion, 
see text for details. 
 
Secretion of FHA is an extremely convoluted process of which the details are still 
emerging. The fhaB gene encodes a 71 aa extended signal peptide (78), a feature that is 
conserved throughout the B. bronchiseptica complex. However, deletion of the extension has 
no observable effect on maturation or function of FHA (unpublished data). Once the signal 
peptide is cleaved in the periplasm, the extended “proprotein,” called FhaB, must find its 
cognate TpsB protein, FhaC, which forms a β-barrel channel in the outer membrane. FhaC 
recognizes the conserved TPS domain in the N-terminus of FhaB via periplasmic POTRA 
domains and secretion to the surface commences (Figure 2) (79–81). Because many TPS 
exoproteins contain β-helical structure, it is hypothesized that the folding of these domains 
provides the energy for secretion through the outer membrane. Evidence suggests that FhaB 
travels through FhaC in an extended hairpin structure, with the β-helical domain folding 
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foremost while the N-and C-termini remain in the periplasm (Figure 2C) (66, 76, 82). 
Eventually, the MCD is secreted and folds, FhaB is cleaved by several proteases (SphB1 and 
an unidentified protease), and the FHA molecule is released (Figure 2C) (65). The order and 
details of these last events remain unknown.  
The last third of FhaB contains the prodomain, a large region of the protein that is 
cleaved off prior to release. Although not much is known about the function of the 
prodomain or the mechanism by which it acts, it is required for the proper folding of FHA 
and remains intracellular during the entire secretion process (66, 68). Bacteria lacking the 
prodomain-encoding sequences of fhaB still secrete FHA in high quantities, but the MCD is 
rendered non-functional (68). Experiments have also shown that specific deletion mutations 
of conserved prodomain regions can inhibit release of FhaB (68). The prodomain has been 
hypothesized to function as a chaperone as well as a tether during secretion, but direct 
evidence for either of these functions is lacking. 
FHA function has been characterized using both in vitro and in vivo models in 
attempts to understand its role during infection. FHA was first recognized as a B. pertussis 
colonization factor that could illicit a protective antibody response (83, 84). Soon after, 
experiments showed that FHA could mediate adherence to a wide range of ciliated and 
nonciliated cell lines in vitro, and was henceforth considered an adhesin (85, 86). In support 
of those studies, experiments using B. bronchiseptica showed that FHA was absolutely 
necessary for the colonization of the lower respiratory tract in rats and mice (67, 87). More 
recently, FHA has also been implicated in modulating the host immune response (63, 67). 
When applied to cultured macrophages, purified FHA can suppress IL-12, modulate the NF-
κB pathway, and induce apoptosis (88, 89). Additionally, B. bronchiseptica that lack FHA 
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cause an infection that is hyperinflammatory, characterized by an influx of IL-17+ 
macrophages, neutrophils, and CD4+ T cells (63). FHA may also have synergistic effects 
with another important virulence factor, ACT. Several studies have shown that FHA and 
ACT can interact on the bacterial cell surface and can influence each other’s secretion (90, 
91). It has been proposed that FHA can enhance the delivery of ACT to host cells.  
Although the function of FHA has been extensively investigated, there are still many 
conspicuous knowledge gaps. For example, the FHA host receptor(s) and cellular targets 
remain unknown. The secretion and processing of FhaB is still poorly understood and very 
little is known about the mechanism of release. Similarly, it has been impossible to determine 
the functions of released and cell-associated FHA because current knowledge prevents the 
creation of appropriate mutants. Testing these hypotheses directly has been a formidable 
challenge, but it is clear that FHA is multi-functional and largely influential to several 
aspects of infection. 
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CHAPTER 2: An improved RIVET-like reporter system reveals differential cyaA gene 
activation in Bordetella species1 
 
Introduction 
 
 Bordetella species are Gram-negative bacterial respiratory pathogens. The genus 
includes Bordetella pertussis, an obligate human pathogen and the causative agent of 
whooping cough, and the closely related Bordetella bronchiseptica, which can infect a wide 
range of mammals including several species that are commonly studied in the laboratory (1-
3). These bacteria rely on the global two-component regulatory system BvgAS for virulence 
(1-3). The BvgAS phosphorelay regulates gene expression patterns according to 
environmental cues and controls at least three distinct phenotypic phases: Bvg minus (Bvg–), 
Bvg plus (Bvg+), and Bvg intermediate (Bvgi) (4, 5). All evidence thus far suggests that the 
Bvg+ phase is necessary and sufficient for infection, and that modulation to the Bvg– or Bvgi 
phase does not occur in vivo (6-8). Although it has been hypothesized that the Bvgi phase 
and/or the Bvg– phase is required for transmission or survival outside of a host (7, 9, 10), a 
recent study provided evidence that neither of these phenotypic phases is required for B. 
bronchiseptica transmission in swine (8).  
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 Genes that define these three phenotypic phases have been divided into four classes 
based on their expression profile. Class 1 (late Bvg+ phase) genes include cyaA-E (encoding 
the bifunctional hemolysin/adenylate cyclase toxin ACT) and ptxA-E (encoding the AB5-type 
pertussis toxin) (4). Class 2 (early Bvg+ phase) genes include those encoding filamentous 
hemagglutinin (fhaB), fimbriae (fim2 and fim3), and bvgAS itself (4). bipA is the only class 3 
(Bvgi phase) gene that has been characterized. Class 4 (Bvg– phase) genes include those 
encoding proteins involved in motility (frlAB) and chemotaxis in B. bronchiseptica (4).  
 Expression of genes that define the various Bvg-dependent phenotypic phases is 
determined mechanistically by the location and affinity of BvgA binding sites near the 
transcription start site (4). Class 1 genes contain multiple low affinity BvgA binding sites 5′ 
distal to the start of transcription (4, 11), while class 2 genes contain high-affinity BvgA 
binding sites proximal to the transcription start site (12-14). The promoter region of the class 
3 gene bipA contains high affinity BvgA binding sites 5′ proximal to the transcription start 
site and low affinity sites 3′ to the transcription start site (10, 15). Although it has been 
hypothesized that BvgAS directly represses transcription of frlAB in B. bronchiseptica (16), 
BvgA binding to the frlAB promoter has not been demonstrated and BvgAS-mediated 
repression of at least some genes in B. pertussis is indirect (17). 
 In vitro transcription and DNA binding studies indicate that the phosphorylated form 
of BvgA (BvgA~P) is required to activate transcription of Bvg+ phase genes and that a higher 
concentration of BvgA~P is necessary to bind “late” Bvg+ phase promoters than “early” Bvg+ 
phase promoters (11, 18). Although the natural signals that activate the BvgAS system are 
unknown, it is possible to modulate Bordetella spp. to the Bvg– phase in the laboratory by 
adding a chemical modulator (MgSO4 or nicotinic acid) to the growth medium, or by 
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growing bacteria at 25°C (15, 19-21). When grown under Bvg– phase conditions, class 4 
genes are expressed while class 1–3 genes are not expressed. When switched from Bvg– 
phase to Bvg+ phase conditions, transcription of class 4 genes ceases and transcription of 
class 2 genes, along with the sole class 3 gene bipA, is immediately activated. After several 
hours, class 1 genes are expressed and class 3 (bipA) genes are repressed. These data are 
consistent with the model in which the concentration of BvgA~P within the cell is nearly 
zero in the Bvg– phase, low in the Bvgi phase, and high in the Bvg+ phase (4, 5, 11, 15, 18, 
22, 23). 
 By contrast with the extensive in vitro characterization of the steady-state expression 
patterns of BvgAS-regulated genes in both B. pertussis and B. bronchiseptica, as well as 
kinetic analyses of gene expression upon switching from modulating to non-modulating 
conditions and vice versa (5, 10, 11, 15, 22-24), only one study has investigated BvgAS-
dependent gene regulation in vivo (24). Veal-Carr et al. utilized recombination-based in vivo 
expression technology (RIVET) to analyze the kinetics of BvgAS-activated gene expression 
in B. pertussis both in vitro and following intranasal infection of mice (24, 25). They showed 
that the in vivo activation of Bvg+ phase genes, including ptxA, cyaA, fhaB, and prn, 
temporally recapitulated the activation pattern of these genes upon switching B. pertussis 
from Bvg– to Bvg+ phase conditions in vitro; i.e., fhaB was activated early post-inoculation 
(~1 h), followed by prn (~4 h), then later by cyaA (~12 h) (24). Significantly, the fact that the 
pattern of gene activation was nearly identical in bacteria switched from Bvg– to Bvg+ phase 
conditions in vitro and post-inoculation of mice indicates that the mouse lung is a Bvg+ phase 
environment (24).  
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  We constructed a plasmid, pGFLIP, that encodes a Flp recombinase-based 
fluorescent reporter system to assess the activation kinetics of genes in vivo (26). The region 
of pGFLIP delivered to the chromosome contains gfp and nptII genes, encoding green 
fluorescent protein and neomycin phosphotransferase (conferring kanamycin resistance 
[Kmr]), respectively, flanked by Flp recombinase target (FRT) sites. The plasmid also 
contains a promoterless flp recombinase gene with a multiple cloning site (MCS) 
immediately 5′ to the start codon. Upon expression of flp under the control of a promoter of 
interest, the gfp and nptII genes are permanently excised from the bacterial chromosome. 
 To test our system, we cloned the promoter regions of several BvgAS-controlled 
genes, including the Bvg-activated genes cyaA, fhaB, and ptxA and the Bvg-repressed gene 
flaA (encoding flagellin) into pGFLIP and evaluated transcription activation in vitro and in 
vivo in B. bronchiseptica. Amongst other results, we found unexpectedly that the cyaA gene 
is expressed differently in B. pertussis and B. bronchiseptica.  
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Materials and Methods 
 
 Strains, reagents, and growth conditions. Escherichia coli were grown in lysogeny 
broth (LB; 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl) or on LB plates with 1.5% agar at 
37°C. Bordetella were grown in Stainer-Scholte (SS) broth (27) or on Bordet-Gengou (BG) 
plates with 1.5% agar (BD Biosciences, San Jose, CA) supplemented with 7.5% (B. 
bronchiseptica) or 15.0% (B. pertussis) defibrinated sheep’s blood (Colorado Serum 
Company, Denver, CO) at 37°C (28). As required, culture media were supplemented with 
kanamycin (Km; 50 or 100 μg/ml), ampicillin (100 μg/ml), streptomycin (25 μg/ml), MgSO4 
(20 mM or 50 mM), heptakis (1 mg/ml, Sigma), and for the Δasd ΔaphA mobilizer strain 
RHO3 (29), diaminopimelic acid (DAP; 400 μg/ml). Unless otherwise noted, all restriction 
enzymes and T4 DNA ligase was purchased from New England Biolabs. 
 Construction of pGFLIP and derivatives containing Bordetella promoters. The 
Tn7 transposition plasmid pUC18T-mini-Tn7T-Km-FRT (30) was digested with BamHI, 
resulting in fragments of 3636 and 1299 bp in length containing the plasmid backbone and 
the nptII (Kmr) gene, respectively. Separately, a 797-bp fragment containing gfp driven by 
the constitutive Burkholderia pseudomallei rpsL promoter PS12 was amplified by PCR from 
mini-Tn7-kan-gfp (31) using Pfu Ultra II (Agilent) and primers GFP_UP and GFP_DN. This 
fragment was blunt-end ligated into the cloning vector pJET1.2/blunt (Fermentas) and was 
transformed into E. coli DH5α according to the manufacturer’s instructions. Using restriction 
sites introduced by PCR, the PS12-gfp fragment was digested from pJET using BamHI and 
was ligated together with the BamHI-digested pUC18T-mini-Tn7T-Km-FRT backbone and 
nptII fragment. As the flp gene would be sensitive to transcription read-through from either 
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the PS12 or the nptII promoter, primers specific to gfp (gfpseqR) and nptII (kanseqR) were 
used to confirm that both genes would be transcribed opposite the promoter of interest and 
would therefore not drive flp expression. Once the orientation of gfp and nptII was verified, 
the plasmid was digested with KpnI and StuI; a fragment containing promoterless flp 
amplified by PCR from pFLPe4 (30) using primers FLP_UP and FLP_DN was likewise 
digested with KpnI and StuI and was ligated into the digested vector. The resulting plasmid, 
pGFLIP, thus contained an MCS 5′ to flp, the flp recombinase gene, and constitutively 
expressed nptII and gfp genes flanked by FRT sites. pGFLIP was fully sequenced using a 
primer-walking approach with the primers listed in Table 2. 
 Promoters for five Bordetella genes (cyaA, cyaABp, fhaB, ptxA, and flaA) were cloned 
into the MCS of pGFLIP as follows. For cyaA and cyaABp, 605 and 604-bp fragments 
containing the cyaA promoter were amplified by PCR from B. bronchiseptica RB50 and B. 
pertussis BPSM, respectively, using primers cyaA_F and cyaA_R. These fragments were 
digested with SacI and KpnI and ligated into pGFLIP. For fhaB, a 426-bp fragment 
containing the fhaB promoter was amplified by PCR from RB50 using primers fhaprF2 and 
fhaprR2, digested with SacI and KpnI, and ligated into pGFLIP. For ptxA, a 454-bp fragment 
containing the ptxA promoter was amplified by PCR from BPSM using primers ptxprF and 
ptxprR, digested with SacI and ApaI, and ligated into pGFLIP. For flaA, a 514-bp fragment 
containing the flaA promoter was amplified by PCR from RB50 using primers flaA_F and 
flaA_R, digested with SacI and KpnI, and ligated into pGFLIP. These constructs were 
delivered to the chromosome by transposase-mediated insertion as described below. 
 Transposase-mediated delivery of pGFLIP to the B. bronchiseptica attTn7 site. 
The pGFLIP plasmid was delivered to Bordetella by tri-parental mating using a procedure 
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modified from (28). B. bronchiseptica strains RB50 and RB52 were grown on BG agar for 
48 h, and a portion of the cells was co-incubated with conjugation-competent E. coli RHO3 
cells (29) harboring pGFLIP and RHO3 cells containing the helper plasmid pTNS3 (30), 
which expresses tnsABCD from a constitutive promoter, on BG agar supplemented with DAP 
for 6 h at 37°C. Following incubation, cells were restreaked onto BG/Km agar containing 20 
mM MgSO4 (to maintain strains containing pGFLIP with Bvg+ phase promoters in the Bvg– 
phase) or without MgSO4 (to maintain RB50flaAFLP in the Bvg+ phase) and were incubated 
an additional 48 h at 37°C. Delivery of pGFLIP to BPSM followed the same procedure 
except that incubations required four days at 37°C and plates were supplemented with 50 
mM MgSO4. pGFLIP without a promoter driving flp was used as a positive control for GFP 
production and as a negative control for flp activation. The delivery of all constructs to the 
attTn7 site was confirmed by PCR using primers glmSF and gfpseqR (data not shown). 
Evaluation of pGFLIP in vitro. We determined the functionality of pGFLIP using a plate-
based assay in which RB50cyaAFLP and RB50flaAFLP were modulated between promoter-
inactive and promoter-active conditions. BG agar containing 20 mM MgSO4 was used to de-
repress PflaA and to deactivate PcyaA, while BG agar without MgSO4 was used to activate PcyaA 
and to repress PflaA (7). The pGFLIP strains were grown under promoter-inactive conditions 
for 48 h at 37°C and were determined to be GFP+ using a G:BOX Chemi imaging system 
with an UltraBright-LED Blue transilluminator and a SW06 short-pass filter (495–600 nm; 
Syngene, Frederick, MD). A single GFP+ colony was resuspended in PBS and was diluted 
and plated on BG agar under promoter-active and promoter-inactive conditions. To 
demonstrate the loss of Kmr upon promoter activation, Km (100 μg/ml) was added to some 
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plates. Plates were incubated for 48 h at 37°C, and white-light and fluorescent images were 
obtained using the G:BOX Chemi system. 
For kinetic assays, strains containing pGFLIP were grown overnight with Km selection in SS 
under promoter-inactive conditions (20 mM MgSO4 for RB50cyaAFLP, RB50cyaABpFLP, 
RB50fhaBFLP, and RB50ptxAFLP; no added MgSO4 for RB50flaAFLP). Cells were washed 
twice in PBS with or without 5 mM MgSO4 to prevent the premature activation of Bvg+ 
phase and flaA promoters, respectively, and were added to fresh SS medium under promoter-
active conditions (20 mM MgSO4 for RB50flaAFLP; no added MgSO4 for RB50cyaAFLP, 
RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP) at the OD600 that was equivalent to 1 × 
109 cfu/ml. Tubes were incubated on a roller at 37°C for 8 h. At each time point, an aliquot 
of cells was removed, diluted in PBS under promoter-inactive conditions, and was plated on 
BG agar under promoter-inactive conditions. Plates were incubated for 48 h at 37°C, and 
total cfu were enumerated. For kinetic assays with B. pertussis, cultures were inoculated at 
the cfu/ml corresponding to an OD600 of ~ 0.1, and cells were grown overnight in SS 
containing 50 mM MgSO4, 100 μg/ml Km, and 1 mg/ml heptakis. Cells were washed in PBS 
containing 25 mM MgSO4 to prevent premature flp activation. All other aspects of the assay 
were the same as for B. bronchiseptica, except that dilutions were plated on BG agar 
containing 50 mM MgSO4 and plates were incubated four days at 37°C. GFP fluorescence 
was quantified using the G:BOX Chemi imaging system as described. The percent resolution 
(the ratio of GFP– colonies to the total number of colonies × 100%) was calculated for each 
strain at each time point. 
 Evaluation of pGFLIP in a murine model of infection. Five- to seven-week-old 
BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were inoculated intranasally with 1 × 
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105 cfu of B. bronchiseptica pGFLIP strains in 50 µl of PBS. For infections with 
RB50cyaAFLP, RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP, bacteria were grown 
overnight in SS medium containing Km (100 μg/ml) and 20 mM MgSO4 to maintain cells in 
the Bvg– phase. For infections with RB50flaAFLP, bacteria were grown overnight in SS 
media containing Km (100 μg/ml) to maintain cells in the Bvg+ phase. Lungs were harvested 
from infected mice at 1 h and 30 h post-inoculation (p.i.). For RB50flaAFLP, right lungs 
were homogenized in 1 mL of PBS, diluted in PBS, and plated in duplicate on BG agar. For 
strains containing Bvg+ phase promoters in pGFLIP, homogenization, dilution, and plating 
were carried out in the presence of 20 mM MgSO4. Percent resolution was calculated for 
each strain at each time point. This study was done in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. Our protocol was approved by the University of North Carolina IACUC 
(12-307.0). All animals were properly anesthetized for inoculations, monitored regularly, 
euthanized when moribund, and efforts were made to minimize suffering. 
 Statistical analyses. Statistical analyses were performed using Prism 5 (GraphPad 
Software, Inc.). Statistical significance was determined using the unpaired Student’s t-test or 
analysis of variance (ANOVA). Images were formatted using Adobe Photoshop CS5 and 
figures were generated using Adobe Illustrator CS5 (Adobe Systems, Inc.). 
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Results 
 
Design and Construction of pGFLIP. To study transcription activation of genes both in 
vitro and in vivo, we engineered a reporter system, pGFLIP, that provides both fluorescent 
and selectable markers. We designed our system for simplicity and ease of use. Therefore, all 
of the components necessary for pGFLIP function are contained on a single plasmid. The 
region of pGFLIP delivered to the chromosome includes gfp and nptII, each under the control 
of a strong constitutive promoter and together flanked by FRT sequences (Figure 3). The Flp 
recombinase gene flp is present in the opposite orientation from gfp and nptII with an 
immediate 5′ MCS to facilitate the insertion of a promoter of interest. In the absence of 
promoter activity flp is not transcribed and cells remain GFP+ and Kmr. When the promoter 
of interest is activated, flp is transcribed and the gene product mediates recombination 
between FRT sites, permanently excising gfp and nptII.  
  To test the system, we cloned promoter regions from B. bronchiseptica and B. 
pertussis into the MCS to generate the strains described in Table 1. The region of pGFLIP 
between Tn7L and Tn7R ends was delivered to the attTn7 site 3′ to the glmS gene in 
Bordetella spp. as described in Materials and Methods. Transcription terminators are present 
near the 5′ end of the transposon to prevent transcription read-through from glmS. Delivery 
of promoterless pGFLIP to B. bronchiseptica RB50 and B. pertussis BPSM resulted in 
strains that were stably GFP+ and Kmr. These strains did not lose GFP fluorescence or Kmr 
when passaged multiple times in vitro in the absence of selection (data not shown).  
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Figure 3. Design and mechanism of pGFLIP. (A) Diagram of pGFLIP. Tn7R and Tn7L, 
left and right ends of the Tn7 transposon, respectively; T0 and T1, bacteriophage λ and 
E. coli rrnB transcriptional terminators, respectively; FRT, Flp recombinase target; gfp, 
green fluorescent protein gene; nptII, neomycin phosophotransferase gene; MCS, 
multiple cloning site with restriction sites indicated; flp, Flp recombinase gene; oriT, 
origin of conjugative transfer; ori, ColE1 origin of replication; bla, β-lactamase gene. 
(B) Schematic illustration of Tn7-mediated delivery and Flp-mediated excision of 
pGFLIP in RB50. The region of pGFLIP flanked by Tn7L and Tn7R sequences is 
delivered to the attTn7 site located between glmS and BB4801. While the promoter 
driving expression of the gene of interest (Pgene) remains inactive, gfp and nptII are 
expressed constitutively, resulting in fluorescent and Kmr bacteria. When Pgene is 
activated, flp is expressed and Flp recombinase mediates site-specific recombination 
between FRT sites, permanently excising gfp and nptII and yielding bacteria that are 
non-fluorescent and sensitive to Km. 
  
36 
Table 1. Strains and plasmids used in this study 
 
Strain or Plasmid Description Source or reference 
Strains   
E. coli   
DH5α Molecular cloning strain (28) 
RHO3 Conjugation strain; Kms, Δasd, ΔaphA (29) 
Bordetella   
RB50 Wild-type B. bronchiseptica strain; Smr (7) 
RB52 RB50 containing bvgAS from BP338; Smr (22) 
BPSM Smr Tohama I derivative (29, 42) 
RB50FLP RB50 with promoterless pGFLIP integrated at attTn7 This study 
RB50cyaAFLP RB50 with flp recombinase driven by PcyaA integrated at attTn7 This study 
RB50cyaABpFLP 
RB50 with flp recombinase driven by PcyaA from 
Tohama I integrated at attTn7 This study 
RB52cyaABbFLP 
RB52 with flp recombinase driven by PcyaA from 
RB50 integrated at attTn7 This study 
RB52cyaABpFLP 
RB52 with flp recombinase driven by PcyaA from 
Tohama I integrated at attTn7 This study 
RB50fhaBFLP RB50 with flp recombinase driven by PfhaB from RB50 integrated at attTn7 This study 
RB50ptxAFLP RB50 with flp recombinase driven by PptxA from Tohama I integrated at attTn7 This study 
RB50flaAFLP RB50 with flp recombinase driven by PflaA integrated at attTn7 This study 
BPSMFLP BPSM with promoterless pGFLIP integrated at attTn7 This study 
BPSMcyaAFLP BPSM with flp recombinase driven by PcyaA from RB50 integrated at attTn7 This study 
BPSMfhaBFLP BPSM with flp recombinase driven by PfhaB from RB50 integrated at attTn7 This study 
BPSMptxAFLP BPSM with flp recombinase driven by PptxA integrated at attTn7 This study 
Plasmids   
pUC18T-mini-Tn7T-Km-
FRT Mobilizable transposition vector; Ap
r, Kmr (30) 
pFLPe4 Site-specific excision vector, source of Flp recombinase; Apr, Kmr (30) 
mini-Tn7-kan-gfp Mobilizable transposition vector, source of gfp driven by PS12; Kmr 
(31) 
pTNS3 Tn7 transposase expression vector containing tnsABCD; Apr (30) 
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pGFLIP pUC18-based vector with PS12-gfp and nptII flanked by FRT sequences and flp 3′ to the MCS; Apr, Kmr  This study 
pGFLIP-PcyaA 
pGFLIP with flp recombinase driven by the RB50 
cyaA promoter, Apr, Kmra  This study 
pGFLIP-PcyaABp 
pGFLIP with flp recombinase driven by the BPSM 
cyaA promoter, Apr, Kmra  This study 
pGFLIP-PfhaB 
pGFLIP with flp recombinase driven by the RB50 
fhaB promoter, Apr, Kmra  This study 
pGFLIP-PptxA 
pGFLIP with flp recombinase driven by the BPSM 
ptxA promoter, Apr, Kmra  This study 
pGFLIP-PflaA 
pGFLIP with flp recombinase driven by the RB50 
flaA promoter, Apr, Kmra  This study 
aKmr only under promoter-inactive conditions 
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Table 2. Primers used in this study 
 
Primer Sequence (5′-3′)a Description 
FLP_UP ATCTACGGTACCATGAGCCAGTTCGATATCC Forward and 
reverse primers to 
amplify flp from 
pFLPe4 
FLP_DN AGGTCCAGGCCTCTATATGCGTCTATTTATG 
GFP_UP ATATATGGATCCCAGCTGTTGACTCGCTTG Forward and 
reverse primers to 
amplify gfp from 
mini-Tn7-kan-gfp 
GFP_DN ACCTGGGGATCCTTATTTGTATAGTTCATCC 
Tn7seqF GAGCGCTTTTGAAGCTGATGTGCT 
Forward 
sequencing primer 
annealing within 
Tn7R 
gfpseqR GATGACGGGAACTACAAGACACGT 
Reverse sequencing 
primer annealing 
within gfp 
kanseqR ATCGCCTTCTATCGCCTTCTTGAC 
Reverse sequencing 
primer annealing 
within nptII 
GFLseq1 ACGGTGAAAACCTCTGACACATGC 
Forward 
sequencing primers 
for sequencing 
pGFLIP by primer-
walking 
GFLseq2 CTGAAATCAGTCCAGTTATGCTGTG 
GFLseq3 AAATCCGCCGCTAGGAGCTT 
GFLseq4 GTCTGCCATGATGTATACATTGTGTG 
GFLseq5 GGGACAACTCCAGTGAAAAGTTCTTC 
GFLseq6 CTGATGCTCTTCGTCCAGATCATC 
GFLseq7 CCTGCGTGCAATCCATCTTGTTCA 
GFLseq8 CAGGGGATCTTGAAGTTCCTATTCCG 
GFLseq9 GCAACAATTCTGGAAGCCTCATT 
GFLseq10 TCTTTAGCGCAAGGGGTAGGATCG 
GFLseq11 TCCAATTGAGGAGTGGCAGCAT 
GFLseq12 TATCAGAGCTTATCGGCCAGCCT 
GFLseq13 ATAAAGATACCAGGCGTTTCCCCC 
GFLseq14 AAACAAACCACCGCTGGTAGC 
GFLseq15 CGCAGAAGTGGTCCTGCAACTTTA 
GFLseq16 CCGCGCCACATAGCAGAACTTTAA 
gflpmcsF GTTGACAAAGGGAATCAGGGGATC  
Forward 
sequencing primer 
for inserts in the 
MCS 
gflpmcsR GAACTGGGTGTAGCGTCGTAAGCT Reverse sequencing primer for inserts in 
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the MCS 
glmSF CAGCTGCTGTCGTACCACACGG 
Forward primer to 
confirm Tn7 
insertion at glmS by 
PCR 
cyaA_F ATTATAGAGCTCTGCGAGCAGATGCAC Forward and 
reverse primers to 
amplify PcyaA from 
RB50 and BPSM 
cyaA_R TATAATGGTACCGTGGATCTGTCGATAAGTAG 
ptxprF AGCTTCGAGCTCCAAGATAATCGTCCTGCTC Forward and 
reverse primers to 
amplify PptxA from 
BPSM  
ptxprR ATATATGGGCCCTCCCGTCTTCCCCTCT 
fhaprF2 AGGCCTGAGCTCGATAAGAAGAATATGCTT Forward and 
reverse primers to 
amplify PfhaB from 
RB50 
fhaprR2 ATATTCGGTACCATTCCGACCAGCGAAGTG 
flaA_F AATGAGCTCGCCGTGCTCAACGTCA Forward and 
reverse primers to 
amplify PflaA from 
RB50 
flaA_R ATTATAGGTACCAGGCTCCCAAGAGAGAAA 
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Functional evaluation of pGFLIP in vitro. To evaluate the functionality of pGFLIP, we 
used two B. bronchiseptica promoters for which activity can readily be induced in vitro: PcyaA 
and PflaA. In B. bronchiseptica, the flaA promoter is highly transcribed in the Bvg– phase, 
while the cyaA promoter is transcribed strongly in the Bvg+ phase (9, 10, 15, 22, 32). 
Therefore, RB50flaAFLP was constructed under Bvg+ phase conditions to prevent expression 
of flaA, while RB50cyaAFLP was maintained under Bvg– phase conditions to prevent 
expression of cyaA. Km was added to the media during construction of these strains to select 
against any bacteria that had activated flp, thus ensuring that the population only contained 
GFP+ and Kmr cells. To test these strains for pGFLIP functionality, we suspended a single 
GFP+ colony of each strain in PBS and plated on BG, BG/Km, BG/MgSO4, and 
BG/Km/MgSO4 agar and observed colony formation and GFP fluorescence after two (B. 
bronchiseptica) or four (B. pertussis) days incubation at 37°C.  
 When plated under promoter-active conditions (20 mM MgSO4 for RB50flaAFLP; no 
added MgSO4 for RB50cyaAFLP) in the absence of Km, all RB50flaAFLP and 
RB50cyaAFLP colonies examined had lost fluorescence, and when tested subsequently for 
growth on agar containing Km, all colonies had lost Kmr (Figure 4 A and D). As expected, 
plating either strain under promoter-active conditions and in the presence of Km resulted in a 
lack of growth due to loss of nptII from the chromosome (Figure 4 E and H). Conversely, 
when plated under promoter-inactive conditions (no added MgSO4 for RB50flaAFLP; 20 
mM MgSO4 for RB50cyaAFLP) in the presence of Km, all RB50flaAFLP and RB50cyaAFLP 
colonies maintained fluorescence (Figure 4 F and G). Likewise, under promoter-inactive 
conditions in the absence of Km, all RB50flaAFLP colonies maintained fluorescence (Figure 
4 
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Figure 4. Plate-based validation of the pGFLIP reporter system using PcyaA and PflaA. 
Left column, images of RB50cyaAFLP plated under (A) Bvg+ phase and (C) Bvg– phase 
conditions (achieved by supplementing BG agar with 20 mM MgSO4) in the (E) 
presence or (G) absence of 100 μg/ml Km. Right column, images of RB50flaAFLP 
plated under (B) Bvg+ phase and (D) Bvg– phase conditions in the (F) presence or (H) 
absence of 100 μg/ml Km. White light photographs are on the left and fluorescent 
images are on the right in each pair of images.  
 
B), indicating that flaA is not expressed under these conditions. Unexpectedly, however, 
when RB50cyaAFLP was plated under promoter-inactive conditions in the absence of Km 
selection, approximately 14% of the colonies had lost fluorescence at the time of imaging 
(Figure 4C). These colonies did not grow when restreaked onto BG/Km/MgSO4, indicating 
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that cells in these colonies were not gfp mutants but had lost fluorescence and Kmr due to 
Flp-mediated recombination. These results suggest that the transcription activity of PcyaA 
under Bvg– phase conditions in vitro is close to the threshold level of flp transcription 
required for Flp-mediated recombination between FRT sites. These plate-based assays for 
fluorescence and Kmr demonstrated that pGFLIP is indeed functional and that both markers 
(gfp and nptII) can be used to document promoter activation under active and inactive 
conditions. 
 
Kinetic analysis of Bordetella gene activation using pGFLIP. We next assessed the ability 
of this system to monitor gene activation over time in bacteria grown in liquid culture. 
Strains containing pGFLIP plasmids with cyaA, fhaB, ptxA, and flaA promoters were grown 
overnight under promoter-inactive conditions, switched to promoter-active conditions, and 
the percent resolution (i.e., loss of GFP fluorescence and Kmr) was calculated over 8 h. For 
the first 4 h after switching from Bvg+ phase to Bvg– phase conditions, the percentage of 
RB50flaAFLP colonies that had lost fluorescence remained below 20% (Figure 5A), 
indicating that less than 20% of the bacteria had reached or surpassed the threshold of flp 
expression to result in recombination during this time. Approximately 75% of cells had lost 
fluorescence at 6 h, and this proportion was maintained at 8 h (Figure 5A). When grown 
under Bvg– phase conditions for 24 h, greater than 85% of cells demonstrated a loss of 
fluorescence and Kmr (data not shown). The fact that resolution did not reach 100% suggests 
that the maximum  
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Figure 5. Kinetic analysis of Bordetella gene activation in vitro. B. bronchiseptica strains 
grown under promoter-off conditions and in the presence of 100 μg/ml Km were 
washed and placed in fresh SS medium under (A) promoter-on conditions or (B) 
promoter-off conditions. Colonies arising from aliquots plated over 8 h were monitored 
for loss of fluorescence and the percent resolution was calculated. Results are the mean 
± SEM for experiments performed in duplicate or triplicate. 
 
level of flaA expression under in vitro Bvg– phase conditions (SS medium containing 20 mM 
MgSO4) is just at or above the threshold of flp expression needed for Flp-mediated 
recombination between FRT sites. The relatively long amount of time required for the 
majority of RB50flaAFLP cells to cross the threshold of flp expression is in agreement with a 
previous study that examined the expression kinetics of the BvgAS-regulated operon frlAB, 
which encodes the E. coli FlhDC homologs FrlAB that are at the top of the flagella 
transcription cascade in B. bronchiseptica (16). Upon shifting from Bvg+ phase to Bvg– 
phase conditions, a frlAB-lacZ fusion strain exhibited a gradual increase in β-galactosidase 
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activity over time, reaching approximately 40% of the maximum overnight expression level 
by 7.5 h (15).  
 In contrast, when RB50fhaBFLP were switched from Bvg– phase to Bvg+ phase 
conditions, the fhaB promoter was apparently activated as early as 1 h, at which time 
approximately 75% of cells had lost fluorescence (Figure 5A). At 2 h and later time points, 
nearly 100% of RB50fhaBFLP cells had lost fluorescence, consistent with the classification 
of fhaB as a class 2 gene requiring a relatively low level of BvgA~P for activation. As a 
canonical class 1 (or “late”) gene, ptxA had only been activated in approximately 8% of cells 
at 1 h (Fig. 3A). Approximately 20% of cells had activated ptxA by 4 h, increasing to 90% of 
cells by 8 h. Surprisingly, cyaA, which is also considered to be a class 1 gene, was activated 
in over 85% of cells at 1 h, and in greater than 95% of cells at 2 h and later time points (Fig. 
3A). These data suggest that at early time points after switching to promoter-active 
conditions, the cyaA promoter is activated to a level sufficient to drive flp-mediated 
recombination. This result was unexpected based on cyaA transcription results in studies of 
B. pertussis (5, 11, 18, 23, 24). 
 At the initiation of each kinetic experiment, we observed a consistent background 
resolution (i.e., the percent resolution at 0 h) for each Bvg+ phase promoter in pGFLIP. 
RB50cyaAFLP displayed the highest background resolution at 8.9%, while the background 
resolution for fhaB and ptxA was significantly lower at 1.54% and 1.99%, respectively (p < 
0.01). The background resolution for RB50flaAFLP was the lowest of the pGFLIP constructs 
at 0.23% (Figure 5A). The fact that a portion of RB50cyaAFLP cells had lost fluorescence at 
0 h suggests that low-level expression of cyaA might be occurring in a BvgAS-independent 
manner, which could interfere with measuring BvgAS-dependent PcyaA activation over time. 
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Therefore, to test the sensitivity of pGFLIP to background resolution we grew 
RB50cyaAFLP, RB50fhaBFLP, and RB50ptxAFLP strains overnight as in Fig. 3A, washed 
the cells to remove Km, and maintained the cultures under Bvg– conditions in the absence of 
selection for 8 h. At 0, 1, 4, and 8 h, the percent resolution was determined for each strain. 
We hypothesized that if PcyaA was indeed active under Bvg– conditions we would observe a 
steady increase in resolution over time for RB50cyaAFLP but not for RB50fhaBFLP or 
RB50ptxAFLP. As expected, RB50cyaAFLP displayed the greatest background resolution at 
11.9%, increasing to 18.1% at 8 h (Figure 5B). Loss of fluorescence for RB50fhaBFLP and 
RB50ptxAFLP remained essentially unchanged over 8 h, averaging 0.22% and 5.4%, 
respectively (Figure 5B). Although cyaA had been activated in approximately one-fifth of the 
population at 8 h, these data do not account for the >85% resolution observed for 
RB50cyaAFLP as early as 1 h following the switch to Bvg+ phase conditions.   
 
Neither the B. bronchiseptica bvgAS allele nor PcyaA accounts for the unexpectedly early 
activation of cyaA. As cyaA expression in RB50 was activated unexpectedly early compared 
to what has been observed for B. pertussis (5, 11, 18, 23, 24), we sought to determine 
whether differences in the cyaA promoter or in the bvgAS allele between B. bronchiseptica 
and B. pertussis accounted for this difference. There are five single nucleotide changes and 
one nucleotide insertion in the sequence 5′ to cyaA in B. bronchiseptica RB50 compared to 
B. pertussis BPSM. We hypothesized that replacing the cyaA promoter of RB50 with that of 
BPSM would delay the activation of PcyaA relative to PfhaB, similar to what was observed by 
Veal-Carr et al. (24). We cloned the cyaA promoter from B. pertussis BPSM into pGFLIP 
and introduced this plasmid into RB50, generating strain RB50cyaABpFLP. When evaluated 
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in the kinetic assay, there was no difference in the rate of resolution between RB50cyaAFLP 
and RB50cyaABpFLP, suggesting that differences in the cyaA promoter do not account for the 
rapid resolution observed in B. bronchiseptica (Figure 6).  
 Some strains of B. pertussis, such as BP338 and BPSM, exhibit decreased sensitivity 
to chemical modulation compared to B. bronchiseptica RB50 due to amino acid differences 
in BvgS, which causes these strains to remain in the Bvg+ phase at a lower concentration of 
modulator compared to RB50 (22). We hypothesized, therefore, that the bvgAS allele from 
BP338 would permit activation of cyaA more quickly and in a greater percentage of cells 
compared to the B. bronchiseptica RB50 bvgAS allele. To assess this, we utilized strain 
RB52, which contains the entire bvgAS locus and bvgA promoter from B. pertussis BP338 in 
place of bvgAS in RB50 (22). RB52 recapitulates the decreased sensitivity to modulation 
characteristic of both BP338 and BPSM, requiring ≥ 40 mM MgSO4 to modulate to the Bvg– 
phase, in contrast to RB50, which requires ≥ 10 mM MgSO4 to fully modulate (15, 22). We 
introduced pGFLIP containing the RB50 cyaA promoter driving flp expression into RB52, 
producing strain RB52cyaABbFLP. We evaluated the kinetics of cyaA activation in 
RB52cyaABbFLP compared to RB50cyaAFLP and did not observe any difference. Likewise, 
when we evaluated an RB52 derivative containing the BPSM cyaA promoter driving flp 
expression (RB52cyaABpFLP) in the kinetic assay, there was no impact on cyaA activation 
compared to RB50cyaAFLP. Together, these data suggest that neither the cyaA promoter nor 
the bvgAS allele significantly affects the kinetics of cyaA activation in B. bronchiseptica as 
reported by the PcyaA-flp promoter fusion in pGFLIP (Figure 6). 
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Figure 6. Effect of PcyaA and bvgAS alleles on cyaA activation in B. bronchiseptica. RB50 
and RB52, an RB50 derivative carrying the bvgAS allele from B. pertussis BP338 in 
place of the native bvgAS allele, each with pGFLIP containing RB50 and BPSM PcyaA, 
were grown as in Fig. 3 and were switched to promoter-on conditions for 8 h. Loss of 
fluorescence was calculated for each strain as described in Materials and Methods. 
Results are the mean ± SEM for experiments performed in duplicate. 
 
Evaluation of Bordetella promoter activation in vivo. Although the kinetics of Bvg+ phase 
gene activation in vivo have been examined for B. pertussis (24), these experiments have not 
been done in B. bronchiseptica or in the context of a natural bacteria-host interaction. To 
address BvgAS-regulated gene activation in B. bronchiseptica in vivo, we infected BALB/c 
mice intranasally with 1 × 105 cfu of the RB50 pGFLIP strains shown in Figure 5A, grown 
under promoter-inactive conditions (100 μg/ml Km, 20 mM MgSO4). Mice were sacrificed 
and lungs were harvested at 1 h and 30 h p.i. Lungs were homogenized and dilutions were 
plated on BG agar containing 20 mM MgSO4 to prevent further recombination. Total cfu 
were enumerated and the percentage of colonies that had lost fluorescence (% resolution) 
was calculated for each strain and time point. The percentage of RB50fhaBFLP that had lost 
fluorescence at 1 h was 95.3 ± 0.60%, while only 5.4 ± 0.69% of RB50ptxAFLP had lost 
fluorescence at this time (Figure 7). Similar to the in vitro kinetic assay (Figure 5A), the 
majority (85.3 ± 3.3%) of RB50cyaAFLP cells had lost fluorescence at 1 h. At 30 h p.i., 
essentially all cells had lost fluorescence, indicating that the environment in the mouse 
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induces the expression of Bvg+ phase genes to a level at or above that required to activate flp 
expression (Figure 7). The fact that the pGFLIP system functions in vivo much the same as in 
vitro when switched from Bvg– to Bvg+ phase conditions suggests that the pattern of Bvg+ 
phase gene activation is similar between these two conditions and that the unexpectedly early 
expression from the cyaA promoter in vitro was not due to an artifact of that assay.  
 
Figure 7. Analysis of Bordetella gene activation in vivo using pGFLIP. RB50cyaAFLP, 
RB50fhaBFLP, RB50ptxAFLP, and RB50flaAFLP were grown as in Fig. 3 and 1 × 105 
cfu was inoculated intranasally into mice in a total volume of 50 µl. Mice were 
sacrificed at 0, 1, and 30 h p.i., with additional time points at 3, 5, and 7 days for 
RB50flaAFLP, and lungs were homogenized and plated on BG agar supplemented with 
20 mM MgSO4 and Sm (for RB50cyaAFLP, RB50fhaBFLP, and RB50ptxAFLP) or on 
BG agar supplemented only with Sm (for RB50flaAFLP). Loss of fluorescence was 
calculated for each strain as described in Materials and Methods. Results are the mean 
± SEM for experiments performed in duplicate with three mice per time point 
 
Although all evidence thus far suggests that the Bvg+ phase is necessary and sufficient for 
Bordetella spp. to cause respiratory infection in rats and mice (6, 7, 22, 33), it is possible that 
rare in vivo environments exist that induce modulation to the Bvg– phase. Therefore, using 
the activation of the flaA promoter as an indicator of the Bvg– phase, we infected mice as 
described above and evaluated the loss of fluorescence at 1 h and 30 h p.i. We did not 
observe activation of flaA in any RB50flaAFLP cells at 1 h, 30 h, 3 d, 5 d, or 7 d (Figure 7). 
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These data suggest that B. bronchiseptica do not enter the Bvg– phase in the mouse during 
the time period that we examined.  
 
Kinetic analysis of Bordetella gene activation in B. pertussis reveals delayed activation of 
cyaA compared to B. bronchiseptica. Due to the observation that neither the cyaA promoter 
nor the bvgAS allele affects the kinetics of cyaA activation in B. bronchiseptica, we 
hypothesized that additional, species-specific factors account for the differences in the 
activation of cyaA. To evaluate this possibility, we delivered the same pGFLIP plasmids as 
those used in B. bronchiseptica to the chromosome of B. pertussis BPSM and evaluated loss 
of fluorescence in the kinetic assay. We reasoned that if the activation of cyaA, fhaB, and 
ptxA in B. pertussis resembled the pattern seen in B. bronchiseptica, then the discrepancy 
with was likely due to differences in resolvase/recombinase expression sensitivity between 
pGFLIP and RIVET (i.e., Flp recombinase is activated at a lower threshold of PcyaA activity 
than TnpR, making cyaA appear to be activated sooner in the Flp-FRT system). Alternatively, 
if activation of cyaA, fhaB, and ptxA was canonical as in Veal-Carr et al. (24), then the 
difference in cyaA activation would be attributed to species-specific gene regulation. 
 In contrast to what we observed in B. bronchiseptica, the proportion of 
BPSMcyaAFLP that had lost fluorescence at 1 h was less than 10%, essentially equal to the 
level of background resolution (Figure 8). There was a steady loss of fluorescence in 
BPSMcyaAFLP beginning at 2 h post-switch and continuing until 6 h, at which time greater 
than 90% of colonies had lost fluorescence. The pattern of PcyaA activation in B. pertussis 
matched that of PptxA, which displayed similar but somewhat earlier activation in B. pertussis 
compared to B. bronchiseptica (Figure 8). Interestingly, the loss of fluorescence in 
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BPSMfhaBFLP occurred more slowly compared to RB50fhaBFLP, with approximately 55% 
of cells having lost fluorescence at 1 h. At 2 h post-switch the proportion of GFP– 
BPSMfhaBFLP equaled that of RB50fhaBFLP at 1 h, indicating that the activation of PfhaB 
may be delayed in B. pertussis compared to B. bronchiseptica; however, the background 
resolution for BPSMfhaBFLP (29.5 ± 11.3%) was substantially higher compared to 
RB50fhaBFLP. At 1.99%, the background resolution for BPSMptxAFLP was identical to that 
seen for RB50ptxAFLP, while the background for BPSMcyaAFLP (4.8 ± 2.2%) was not 
significantly different compared to RB50cyaAFLP (Figure 8).  
 
 
Figure 8. Kinetic analysis of Bordetella gene activation in vitro in B. pertussis. Strains 
grown under promoter-off conditions and in the presence of 100 μg/ml Km were 
washed and placed in fresh SS medium under promoter-on conditions. Colonies arising 
from aliquots plated over 8 h were monitored for loss of fluorescence and the percent 
resolution was calculated. Results are the mean ± SEM for experiments performed in 
triplicate. 
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Discussion 
  
 Evaluating bacterial gene expression within the host is critical for understanding the 
complex host-pathogen interactions that result in disease, clearance, or asymptomatic 
colonization. One approach that has been developed to evaluate gene expression in the host is 
in vivo expression technology (IVET) (34). In IVET, promoter sequences are cloned 5′ to a 
gene that either confers resistance to an antibiotic or complements a specific auxotrophy (34-
36). Under conditions in which the promoter is active, these genes are expressed and permit 
the survival of bacteria in hosts that have either been dosed with the relevant antibiotic (for 
antibiotic resistance-based selection) or naturally lack the ability to complement the 
auxotrophy (for auxotrophy-based selection) (34). A drawback of using IVET is that 
promoters that are activated transiently or at a low level may not be identified due to 
insufficient production of the missing survival factor (34). In RIVET, a modification of 
IVET, a promoter of interest drives the expression of a site-specific recombinase that 
irreversibly excises a genetic marker, often an antibiotic resistance gene (24, 34, 37). By 
selective plating it is possible to determine if the promoter of interest was active at some time 
during infection. Unlike IVET, RIVET permits the detection of transiently or weakly 
expressed genes because the recombinase-mediated loss of a marker need only occur once to 
document promoter activation (34).  
 pGFLIP is a pUC18-based plasmid that, while conceptually similar to RIVET, 
possesses several advantages over this well-characterized genetic tool. The Tn7 transposon 
system specifically delivers sequences to the attTn7 site located 3′ to the highly conserved 
glmS gene, which provides pGFLIP with an especially broad host range that includes many 
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Gram-negative bacteria (38). As a result of this specific recombination at the attTn7 site, 
only one integration event is required for all components of pGFLIP to be delivered in single 
copy to the bacterial chromosome. Single-copy delivery eliminates potential gene dosage 
issues inherent to multi-copy plasmid systems, and integration at the attTn7 site does not 
disturb the native locus of the gene to be tested. Once delivered, a Tn7 transposon is stable in 
the absence of selection, unlike suicide plasmids that have been integrated into the 
chromosome via single-crossover homologous recombination, which can spontaneously 
resolve in the absence of selection. In contrast with other published systems, pGFLIP also 
possesses two markers—gfp and nptII—allowing either the loss of fluorescence or Kmr to 
indicate promoter activation.  
 In this study, we used pGFLIP to analyze the transcription activation of Bvg-
regulated genes in both B. bronchiseptica RB50 and B. pertussis BPSM. Our results showed 
that, in vitro, fhaB and ptxA promoters were activated early and late, respectively, following a 
switch from Bvg– to Bvg+ phase conditions, which is in agreement with previous reports for 
both Bordetella species (15, 23, 24). However, the cyaA promoter was activated 
unexpectedly early in our assay; these results appear to stand in contradiction to the 
established view that cyaA is transcribed solely as a late gene. Using B. bronchiseptica RB50 
in a BALB/c mouse model, we found that the pattern of gene activation for cyaA, fhaB, and 
ptxA was nearly identical to that observed in vitro at early time points. Veal-Carr et al. 
reported similar agreement between in vitro and in vivo gene activation patterns using 
RIVET (24), although in that study, maximal activation of fhaB, cyaA, and prn occurred over 
a much greater time scale (approximately 24 h to full activation), likely a result of differences 
in sensitivity between the TnpR-res and Flp-FRT systems. Our use of pGFLIP to evaluate 
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gene activation in B. bronchiseptica is both the first kinetic analysis of PcyaA and the first in 
vivo kinetic analysis of any promoter to be reported for this organism.  
Although we expected PcyaA to behave like a class 1 promoter in B. bronchiseptica, based on 
gene activation and expression data obtained by us and others for B. pertussis (5, 11, 18, 23, 
24), our data nevertheless suggest that PcyaA acts more like a class 2 promoter in this 
organism. However, it is not necessarily the case that cyaA reaches maximal expression at 1–
2 h following a switch from Bvg– phase to Bvg+ phase; it is possible that cyaA activation 
occurs in a stepwise manner, i.e., PcyaA may rapidly reach a level of expression necessary to 
activate flp transcription in our system, but may not reach maximal expression until much 
later. This scenario would account for the apparently rapid activation of PcyaA without 
requiring a bacterium to be producing and secreting a significant amount of ACT 
immediately upon switching to non-modulating conditions. Evidence exists to support cyaA 
activation and ACT production, albeit at a reduced level, in the Bvgi phase, as strains RB50i 
and RB53i are slightly hemolytic on BG agar (a consequence of the hemolysin activity of 
ACT), and RB53i produces measurable levels of cyaA transcript (9). We were able to 
determine that neither differences in the cyaA promoter nor in the bvgAS allele between the 
two species accounted for the difference in cyaA activation (see Fig. 4), suggesting that other, 
potentially Bvg-independent, factors may be influencing cyaA activation in B. bronchiseptica 
compared to B. pertussis.  
 In B. pertussis BPSM, PcyaA demonstrated an activation pattern consistent with both 
indirect (RIVET) and direct (RNA hybridization) assessments, reinforcing the conclusion 
that cyaA activation is indeed different between RB50 and BPSM (23, 24). Given the 
differences in host range and the ability of B. bronchiseptica to survive outside of a host (7, 
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9, 10, 33), it is possible that the relatively early activation of cyaA in B. bronchiseptica is 
advantageous during the establishment of infection in a mammalian host or in transmission 
between hosts. Previous studies have shown that RB50 cyaA deletion mutants are more 
susceptible to clearance from the mouse respiratory tract, presumably as a result of 
neutrophil-mediated killing, and that ACT may interact with FHA (an “early” Bvg+ gene) on 
the cell surface and modulate cytokine production by the host (39, 40). All strains of B. 
bronchiseptica that have been tested show the same modulation characteristics in vitro (i.e., 
the same relatively low concentration of modulator is required for inducing the Bvg– phase), 
while B. pertussis isolates exhibit variable resistance to modulation at concentrations of 
modulator equal to or greater than for B. bronchiseptica (22). These observations suggest that 
early expression of cyaA may not be detrimental to human-adapted B. pertussis but may be 
necessary for B. bronchiseptica to establish an infection.  
 For both B. bronchiseptica and B. pertussis it has been shown that the Bvg+ phase is 
necessary and sufficient for infection (6, 7, 9, 16, 22). Our results do not contradict these 
observations for B. bronchiseptica, but demonstrate that once inside the host, bacteria begin 
to transcribe Bvg+ phase genes within 1 h p.i., with essentially every cell having activated 
fhaB, cyaA, and ptxA by 30 h p.i. The transition of B. bronchiseptica from Bvg– phase to 
Bvg+ phase upon inoculation also indicates that the mouse lung is a Bvg+ phase environment. 
We likewise provided evidence that B. bronchiseptica does not modulate to the Bvg– phase 
in vivo, supporting studies conducted using Bvg– phase-locked mutants that were unable to 
establish an infection and were quickly cleared from the respiratory tract and those using 
Bvg+ phase-locked mutants that displayed no colonization defect (7, 8). Moreover, ectopic 
expression of flagellin in Bvg+ phase B. bronchiseptica results in impaired persistence in the 
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rat respiratory tract, possibly due to an immune response to this antigen (16). Therefore, 
modulation to the Bvg– phase likely does not occur in vivo as it would be disadvantageous to 
bacterial survival. We cannot rule out the possibility, however, that some Bvg+ 
RB50flaAFLP bacteria did modulate to the Bvg– phase and were quickly eliminated by the 
immune response, or were present in a niche other than the lung (such as the trachea or 
nasopharnx) and were not represented in the lung homogenates that we analyzed. It is also 
conceivable that B. bronchiseptica is able to partially modulate, perhaps to the Bvgi phase, 
which would not be documented using RB50flaAFLP. We are currently constructing 
additional strains to test this possibility.  
  The pGFLIP plasmid has proven to be useful in understanding the regulation of gene 
activation in Bordetella. However, there remain caveats for the use of this system in other 
applications. As with other IVET and RIVET systems, pGFLIP requires that strains be 
manipulated under strict promoter-inactive conditions to prevent unwanted Flp-mediated 
resolution. This requirement poses problems for studying genes for which conditions of 
repression or lack of activation are unknown, genes that are essential for growth, and for 
genes that may not be fully transcriptionally inactive in vitro. And, like other systems that 
have been developed to monitor transcription, pGFLIP cannot provide information about 
post-transcriptional or post-translational regulation of target genes. Finally, as was shown by 
the variable background resolution of Bvg-regulated promoters in our study, pGFLIP appears 
to be sensitive to low-level promoter activation even under “repressed” conditions for certain 
genes. Lee et al. were able to modulate the sensitivity of RIVET by mutating the ribosome-
binding site (RBS) of tnpR, effectively raising the threshold of promoter activity required for 
resolution (41). pGFLIP does not possess an RBS 5′ to flp, instead relying on the RBS of the 
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promoter of interest, though it would be feasible to develop a modified pGFLIP plasmid that 
contains an RBS with reduced sensitivity to permit the study of genes that are not fully 
inactive or are constitutively active at a low level. 
 In this study we used pGFLIP to detect the activation of BvgAS-regulated genes in 
Bordetella, but there are additional uses for this system to measure transcription activation at 
the population or single cell level. Using pGFLIP, fluorescence can be used to quickly 
differentiate cells that have activated the promoter of interest from those that have not. Over 
time, stochastic and/or transient promoter activation can result in sectoring of fluorescent 
colonies, permitting spatiotemporal observation of gene activation within a single colony (M. 
S. Byrd and E. Mason, unpublished observation). The addition of a second, non-gfp 
fluorescent label (e.g., a constitutively expressed fluorescent protein or a fluorescently 
labeled antibody) to cells already containing pGFLIP would allow cells that had activated the 
promoter of interest to be differentiated from cells that had not. Cells labeled using such an 
approach could be visualized using fluorescence-activated cell sorting or by microscopy. We 
are currently developing an improved pGFLIP plasmid that contains a constitutively 
expressed fluorescent protein gene not flanked by FRT sites that will provide a two-color to 
one-color readout upon activation of flp by the promoter of interest. The development of 
pGFLIP has resulted in a sensitive genetic tool that can be used to document promoter 
activation in a broad range of Gram-negative bacteria both in vitro and in vivo. Our use of 
pGFLIP to document the activation of Bvg-regulated promoters revealed unexpectedly early 
activation of cyaA in B. bronchiseptica, suggesting a possible explanation for the less 
restrictive host range of this organism compared to B. pertussis, and is the first in vivo use of 
a recombination-based genetic reporter of B. bronchiseptica gene activation.  
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CHAPTER 3: Evidence for phenotypic bistability resulting from transcriptional 
interference of bvgAS in Bordetella bronchiseptica1 
 
Introduction: 
The genus Bordetella includes Gram-negative bacteria that cause respiratory 
infections. Bordetella pertussis and Bordetella parapertussishu are strictly human-specific 
pathogens that cause whooping cough, an acute disease that has experienced a recent 
resurgence despite widespread vaccination (1–3). Phylogenetic analyses indicate that B. 
pertussis and B. parapertussishu have recently evolved from Bordetella bronchiseptica, 
which infects a wide range of mammals and can also survive naturally for long periods of 
time outside of the host (4–6). Although the factors that determine host specificity remain 
unknown, the presence and regulation of virulence factor-encoding genes is highly conserved 
between these three sub-species (7, 8). 
Filamentous hemagglutinin (FHA), encoded by the fhaB gene, is a well-characterized 
virulence factor of Bordetella and is a primary component of acellular pertussis vaccines (1, 
9, 10). A prototypical member of the Two Partner Secretion family of proteins, FHA is a 
large, surface-exposed protein that is produced and secreted at a high level during growth in 
vitro (10–12). In B. bronchiseptica, FHA mediates adherence to a wide range of cell lines 
and is required for colonization of the lower respiratory tract in both rats and mice (13–15). 
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Although FHA was first characterized as an adhesin, it has subsequently been reported to 
perform several other important functions. For example, exposure of lipopolysaccharide and 
IFN-γ-stimulated macrophages to purified B. pertussis FHA suppresses interleukin-12 (IL-
12) production, and macrophages treated with FHA exhibit higher rates of apoptosis 
compared to untreated controls (16, 17). FHA-deficient B. bronchiseptica causes an infection 
that is hyperinflammatory compared to infection caused by wild-type bacteria and is 
characterized by increased influx of interleukin-17 (IL-17)-positive neutrophils, 
macrophages, and CD4+ Tcells, suggesting that FHA plays an immunomodulatory role in 
vivo (15, 18). Additionally, there is strong evidence that FHA interacts with another 
important virulence factor, adenylate cyclase toxin ACT (19, 20).  
In Bordetella, the master regulator that controls the expression of all known virulence 
factor-encoding genes is called BvgAS (21). A two-component sensory transduction system, 
BvgAS controls at least three distinct phenotypic phases (Bvg+, Bvgi, and Bvg–) by altering 
gene expression patterns in response to environmental stimuli (Figure 9A) (22). The Bvg+ 
phase is induced during standard laboratory growth conditions at 37ºC on Bordet Gengou 
(BG) blood agar or in Stainer-Scholte broth. Bvg+ phase bacteria are non-motile and form 
small, dome-shaped, hemolytic colonies on BG blood agar. Bacteria can be induced (or 
modulated) to the Bvg– phase in the laboratory by growth at room temperature or by 
supplementing media with millimolar concentrations of chemical modulators such as MgSO4 
or nicotinic acid. Bacteria in the Bvg– phase are motile (B. bronchiseptica only) and form 
large, flat, non-hemolytic colonies. The Bvgi phase can be induced in the laboratory with 
intermediate concentrations of chemical modulators and these bacteria form colonies that 
appear phenotypically intermediate compared to Bvg– and Bvg+ phase colonies. Each 
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phenotypic phase is defined by a unique pattern of gene expression (Figure 9B) (7, 22, 23). 
For example, bacteria in the Bvg+ phase are characterized by maximal expression of 
virulence-activated genes (vags) such as fhaB, cyaA-E (encoding adenylate cyclase toxin 
ACT), ptxA-E (encoding pertussis toxin in B. pertussis), and bvgAS itself (which is positively 
autoregulated). In contrast, Bvg– phase bacteria maximally express virulence-repressed genes 
(vrgs) including those required for motility (i.e., flaA, encoding flagellin and frlAB, the 
Bordetella flhDC homolog) and chemotaxis (B. bronchiseptica only) but do not express vags. 
The vags fall into two classes: those expressed in the Bvgi phase and the Bvg+ phase, and 
those expressed maximally only in the Bvg+ phase. Additionally, some genes, such as bipA, 
are expressed maximally only in the Bvgi phase (24, 25). Thus, Bvgi phase bacteria are 
characterized by maximal expression of bipA, bvgAS, and fhaB, and minimal expression of 
vrgs, cyaA, and ptxA (B. pertussis only) (Figure 9B) (7, 23–26).  
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Figure 9. The Bordetella BvgAS system controls at least four different classes of genes 
and three different phenotypic phases in response to environmental stimuli. A,  BvgAS 
is responsible for the Bvg+, Bvgi, and Bvg– phases and is repressed by chemical 
modulators or low temperature. B, The three phenotypic phases are defined by unique 
patterns of gene expression as indicated, and rely on the intracellular concentration of 
BvgA~P. C, The chromosomal organization of the fhaB and bvgAS loci in RB50 (top) 
and RBX9 (∆fhaB, bottom). Red regions indicate relative BvgA binding regions. 
 
Upon activation of the BvgAS phosphorelay in response to environmental signals, 
BvgS (the sensor kinase) autophosphorylates, becoming the substrate for BvgA (the response 
regulator). BvgA-phosphate (BvgA~P) binds DNA and activates or represses transcription 
(22, 25, 27–30). In vitro transcription and DNA binding experiments have identified both 
high and low affinity BvgA binding sites located at various positions relative to the 
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transcription start sites of BvgAS-regulated genes (22, 25, 27, 30, 31). These data, together 
with a recent report describing a direct assessment of BvgA~P levels in B. pertussis cultures 
(32), support a model in which BvgA~P levels are extremely low under Bvg– phase 
conditions, moderate under Bvgi phase conditions, and high under Bvg+ phase conditions 
(22, 32). In addition to controlling distinct phenotypic phases in response to steady-state 
conditions, BvgAS can regulate gene expression in a temporal manner (27, 33–35). Because 
bvgAS is positively autoregulated, both the concentration of BvgA and the proportion that is 
phosphorylated increase when bacteria sense activating signals. Therefore, gene expression 
patterns change temporally as the total concentration of BvgA~P gradually increases when 
bacteria are switched from Bvg– to Bvg+ phase conditions (27, 33–35).  
The bvgAS and fhaB genes are adjacent and transcribed divergently. The 426 bp 
intergenic region contains at least three promoters (with at least two that control bvgAS, 
called P2 and P1) and multiple high-affinity BvgA binding sites (29, 30, 36, 37) (Figure 9C). 
In the Bvg– phase, bvgAS transcription is driven by the BvgAS-independent promoter P2 that 
is responsible for basal levels of BvgA (which likely remain unphosphorylated) (36, 37). 
When switched to the Bvg+ phase, BvgA becomes phosphorylated and activates fhaB and 
bvgAS via binding to high-affinity sites near PfhaB and P1 (36, 38). Once a relatively high 
concentration of BvgA~P is achieved, genes with low-affinity BvgA binding sites at their 
promoters, such as cyaA and ptxA in B. pertussis, are activated and the bacteria transition into 
the Bvg+ phase (27, 35, 39). The Bvg+ phase, and therefore high levels of BvgA~P, is 
maintained as long as bacteria sense a Bvg+ phase environment. Without bvgAS positive 
autoregulation, the ability of B. bronchiseptica to transition between and maintain each 
phenotypic phase is compromised (35).  
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Data obtained thus far indicate that the Bvg+ phase is necessary and sufficient to 
cause respiratory infection, the Bvg– phase facilitates survival outside of the host, and BvgAS 
modulation to the Bvgi or Bvg– phase does not occur during infection (40–45). For example, 
several groups have shown that Bvg+ phase-locked bacteria behave identically to wild-type 
bacteria in colonization, persistence, and contribution to lung pathology (40, 42–44). In 
contrast, Bvg– phase-locked bacteria cannot establish an infection and Bvgi phase-locked 
bacteria are severely limited in colonization and persistence (23, 40–43). Additionally, we 
recently demonstrated that flaA is not expressed at a detectable level when mice are infected 
with the B. bronchiseptica wild-type strain RB50 (46) and Akerley et. al showed that 
production of flagella in the Bvg+ phase is detrimental to infection (44). Although the natural 
signals that affect BvgAS activity and the role of modulation in nature remain unknown, all 
of these data suggest that wild-type Bordetella do not modulate to the Bvg– phase within the 
mammalian host. 
B. bronchiseptica strain RBX9, which contains an in-frame deletion mutation of fhaB 
(Figure 1C), has been used extensively to characterize the function of FHA in vitro and in 
vivo (11, 13, 15, 18, 47, 48). RBX9 is defective in adherence to multiple cell lines, is unable 
to autoaggregate in liquid culture, and causes hyperinflammation in the murine lung infection 
model (13–15, 18, 48). We isolated large colony variants (LCVs) from mice infected with 
RBX9 and also by modulating RBX9 to the Bvg– phase in vitro. We determined that the 
LCVs were a product of transcriptional interference that influenced bvgAS and produced an 
unusual bistable phenotype. Additionally, and despite evidence suggesting that Bordetella do 
not modulate during infection, the discovery of LCVs indicates that a subpopulation of 
RBX9 bacteria modulates in vivo. 
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Materials and Methods 
 
Strains and growth conditions. Escherichia coli were grown in lysogeny broth (LB; 
10 g l-1 tryptone, 5 g l-1 yeast extract, 2.5 g l-1 NaCl) or on LB with agar (1.5%) at 37°C. 
Bordetella were grown in Stainer-Scholte (SS) broth or on Bordet-Gengou (BG) agar (1.5%) 
(BD Biosciences, San Jose, CA) supplemented with 7.5% defibrinated sheep’s blood 
(Colorado Serum Company, Denver, CO) at 37°C. As required, culture media were 
supplemented with kanamycin (Km; 50 μg ml-1), ampicillin (Ap; 100 μg ml-1), streptomycin 
(Sm; 25 μg ml-1), magnesium sulfate (MgSO4; 50 mM in plates and 20 mM in liquid), and 
diaminopimelic acid (DAP; 400 μg ml-1) for the E. coli mobilizer strain RHO3 (Δasd 
ΔaphA). Unless otherwise noted, all restriction enzymes and T4 DNA ligase was purchased 
from New England Biolabs. For a complete list of strains and plasmids used in this study, 
please see Table S4. 
Construction of bacterial strains. Allelic exchange and Campbell-type integrations 
were done by matings using parental Bordetella and E. coli strain RHO3 harboring the 
appropriate suicide plasmid. The pGFLIP plasmid was delivered to the attTn7 site using tri-
parental mating with the above strains and with RHO3 cells harboring pTNS3, which 
encodes the transposase genes tnsABCD. Integration at the attTn7 locus was confirmed via 
PCR. For details on specific strain constructions see the Supplemental text. 
Immunofluorescence. HA epitopes on the surface of RBX9BatB-HAflaA-gfp 
bacteria were stained and visualized using indirect immunofluorescence. After 72h of growth 
at 37˚C, five to twenty colonies of each morphology including Bvg+, Bvg–, Bvgi, and LCV, 
were scraped off of BG blood agar plates and resuspended into 1ml of 4% paraformaldehyde 
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and were allowed to fix on ice for 30 min. Cells were pelleted and washed with 1% BSA in 
PBS in a microcentrifuge tube. Primary antibody (mouse monoclonal anti-HA IgG diluted 
1:2000 in 1% BSA in PBS) was used to resuspend the pellet and this mixture was incubated 
for 1h at room temperature (RT). The pellets were washed twice in 1% BSA for 5 min. 
Secondary antibody (Alexa Fluor 594-conjugated goat anti-mouse IgG, diluted 1:250 in 1% 
BSA in PBS; Invitrogen) was used to resuspend the pellet and this mixture was then 
incubated for 30 min at RT in the dark. The pellets were washed twice with 1% BSA for 5 
min. Four microliters of the leftover pellet and liquid was pipetted onto a slide for 
visualization. 
Confocal Microscopy. Immunofluorescent RBX9BatB-HAflaA-gfp bacteria were 
visualized using a Zeiss LSM 710 confocal microscope. Secondary antibody (Alexa Fluor 
594-conjugated goat anti-mouse IgG) was detected using a 594 nm laser and GFP was 
detected at 488 nm. We used the 63× oil objective with 3× digital zoom. Images were viewed 
and saved with the Zen software from Carl Zeiss Microscopy. 
pGFLIP assays. For RBX9cyaAFLP, RB50PbvgAshortFLP and RB50PbvgAlongFLP, 
strains were grown on BG blood agar plates under promoter-inactive conditions (Bvg– phase) 
with Km for 48h at 37°C and were determined to be GFP positive (GFP+) using a G:BOX 
Chemi imaging system with an UltraBright-LED blue transilluminator and an SW06 short-
pass filter (495 to 600 nm; Syngene, Frederick, MD). Single GFP+ colonies were then 
resuspended in PBS, diluted, and plated onto Bvg+ or Bvg– phase conditions (promoter-active 
and promoter-inactive conditions, respectively) in the absence of Km selection. For 
RBX9cyaAFLP, GFP+ LCVs were picked, diluted, and plated onto Bvg+ and Bvg– phase 
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conditions in the absence of Km selection. Percent resolution was determined by averaging 
the ratio of GFP– cfu/total cfu for at least three plates.  
Intranasal inoculation of mice. Four- to eight-week-old BALB/c mice (Jackson 
Laboratories, Bar Harbor, ME) were inoculated intranasally with 1×105 cfu of B. 
bronchiseptica in 50 µl of PBS. For all infections, bacteria were grown overnight in SS 
medium. Lungs were harvested at 1h and 72h p.i. Right lungs were homogenized in 1 ml of 
PBS, diluted in PBS, and plated in at least duplicate on BG agar. Figure 16 represents data 
from three independent experiments performed with at least two mice per strain per time 
point.  
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Our 
protocol was approved by the University of North Carolina IACUC (10-134, 12-307). All 
animals were properly anesthetized for inoculations, monitored regularly, euthanized when 
moribund, and efforts were made to minimize suffering. 
Statistical analyses. Statistical analyses were performed using Prism 5.0 (GraphPad 
Software, Inc.). Statistical significance was determined using the unpaired Student’s t-test or 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. Images were 
formatted using Adobe Photoshop CS5 and figures were generated using Adobe Illustrator 
CS5 (Adobe Systems, Inc.). 
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Results 
 
Isolation and characterization of LCVs. While comparing wild-type B. bronchiseptica 
strain RB50 with its ΔfhaB derivative RBX9 in a murine lung infection model, we noticed 
that at early time points post-inoculation (12 and 24 h), a small proportion (~1%) of cfus 
recovered from the lungs of RBX9-inoculated mice formed colonies on BG blood agar (Bvg+ 
phase conditions) that were larger, flatter, and less hemolytic than colonies typically formed 
by RBX9 and RB50 () (Figure 10D). These Large Colony Variants (LCVs) were not 
recovered from RB50-infected mice. When LCVs were picked, diluted, and replated on BG 
blood agar, approximately 95% of the resulting colonies were phenotypically Bvg+ phase, 
and approximately 5% were LCVs (Table 3) (Figure 10H). When replated again, LCVs 
continued to yield 95% Bvg+ phase colonies and 5% LCVs. All phenotypically Bvg+ phase 
colonies yielded only phenotypically Bvg+ phase colonies after replating onto BG agar.  
 
Table 3 LCV recovery frequency 
 
Condition %a LCVs recovered on BG blood agar 
Plating murine lung homogenate after 30 hours 
 
0.39 ± 0.13 
Replating any RBX9 Bvg– phase colony 5.43 ± 0.98 
 
Replating an LCV from BG agar (derived in vitro) 3.90 ± 0.80 
 
Replating an LCV from BG agar (derived in vivo) 
 
6.03 ± 1.26 
Replating any RBX9 Bvg+ phase colony  0 
aValues are means ± standard errors for experiments performed at least in triplicate 
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Figure 10. RB50 and RBX9 colony morphology. Bacteria were plated on either BG agar 
or BG agar + 50mM MgSO4 and were imaged after 48h. A, RB50; B, RBX9; C, RBX9 
LCV produced after in vitro modulation: D, RBX9 LCV recovered from mouse lung 
homogenate; E, RB50i (a Bvg-intermediate phase-locked strain in the RB50 
background); F, RBX9i (a Bvg-intermediate phase-locked strain in the RBX9 
background); G, RBX9 restreak of an LCV produced after modulation; H, RBX9 
restreak of an LCV recovered from the mouse lung; I, RB50; J, RBX9; K, RBX9 
restreak of an LCV produced after modulation; L, RBX9 restreak of an LCV recovered 
from the mouse lung. 
 
We found serendipitously that LCVs were also induced in vitro under certain 
conditions. Specifically, when RBX9 was grown on BG blood agar + 50mM MgSO4 (Bvg– 
phase conditions) and then replated onto BG blood agar—effectively switching the bacteria 
from Bvg– to Bvg+ phase conditions—approximately 95% of the colonies were 
phenotypically Bvg+ phase and 5% were LCVs (Table 3) (Figure 10C). When these LCVs 
were picked, diluted, and replated onto BG blood agar, approximately 95% of colonies 
displayed the Bvg+ phase morphology and approximately 5% of colonies were LCVs (Table 
3) (Figure 10G). Again, all phenotypically Bvg+ phase colonies yielded only phenotypically 
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Bvg+ phase colonies after replating onto BG agar. When RBX9 was streaked onto BG agar 
supplemented with 50mM MgSO4, or passaged continuously under Bvg– phase conditions, 
all colonies displayed typical Bvg– phase morphology.  
To determine if the generation of LCVs in RBX9 was due to the ΔfhaB mutation and 
not an unknown secondary mutation, we reconstructed strain RBX9 by allelic exchange. The 
newly constructed strain behaved identically to RBX9, producing LCVs following BvgAS 
modulation and generating a similar proportion of LCVs upon restreaking an LCV onto BG 
blood agar. Although LCVs appear morphologically similar to Bvgi phase colonies (Figure 
10), the fact that restreaking LCVs yielded a heterogeneous population of morphologically 
different colonies indicates that the ΔfhaB mutation does not lock bacteria into one particular 
phenotypic phase (such as the Bvgi phase.)  
 
LCVs are composed of both Bvg– and Bvg+ phase bacteria. To better understand the 
properties of LCVs, we investigated specific gene expression patterns within the bacteria that 
composed them. The fact that LCVs are hemolytic suggests that cyaA, a Bvg+ phase gene, is 
expressed because ACT is responsible for hemolysis on BG blood agar (49). Additionally, 
electron micrographs of negatively stained LCVs revealed the presence of numerous flagella, 
which are only produced in the Bvg– phase (data not shown). To determine if bacteria within 
LCVs were motile, we grew bacteria on Stainer-Scholte plates with 0.3% agar (Bvg+ phase 
conditions). LCVs stab-inoculated into this agar produced a zone of migration that was 
smaller than that produced by Bvg– phase-locked bacteria, but larger than Bvg+ and Bvgi 
phase bacteria, which do not produce a zone of migration (data not shown), suggesting that at 
least some bacteria within LCVs are motile. Together, our observations indicate that both 
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cyaA and flaA are expressed within each LCV. However, expression data have shown that 
expression of vags, such as cya, and vrgs, such as flaA, is mutually exclusive (7). Therefore, 
we hypothesized that LCVs are composed of at least two phenotypically distinct populations 
of bacteria: a population in the Bvg+ phase and a population in the Bvg– phase. 
To determine the phenotypes of individual bacteria present in each LCV, we created 
RBX9BatB-HAfla-gfp, a strain that contains two unique tags that permit the distinction 
between Bvg+ and Bvg– phase bacteria. RBX9BatB-HAflaA-gfp contains an HA epitope-
encoding sequence introduced into batB (encoding the Bvg+ phase surface-exposed protein 
BatB) as well as gfp driven by the flaA promoter at a neutral site in the chromosome. The 
batB gene is expressed maximally in the Bvg+ phase and minimally in the Bvgi and Bvg– 
phases (50). The flaA gene, as described previously, is a typical vrg and contains a strong 
promoter that is active only in the Bvg– phase (22, 51). Therefore, Bvg+ phase bacteria 
should produce a surface-exposed HA-tagged BatB protein and be GFP– and Bvg– phase 
bacteria should be GFP+ and lack a surface-exposed HA epitope.  
We used Alexa-Fluor 594-conjugated antibodies to indirectly recognize HA epitopes 
so that BatB-producing bacteria displayed red fluorescence. Bacteria expressing fla-gfp 
produced GFP and displayed green fluorescence. When Bvg+ phase colonies of RBX9BatB-
HAfla-gfp were stained with anti-HA and an Alexa-Fluor 594-conjugated secondary 
antibody, only red-fluorescing bacteria were observed and no green fluorescence was 
detected (Figure 11.) 
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Figure 11. Detection of Bvg+ (α-HA, red) and Bvg– phase (flaA-gfp, green) bacteria in 
typical RBX9 colonies and LCVs. RBX9BatBN-HAflaA-gfp was grown on BG blood 
agar (Bvg+ phase conditions), BG blood agar + 50 mM MgSO4 (Bvg– phase conditions), 
or BG blood agar + 6 mM MgSO4 (Bvgi phase conditions). Several colonies of each 
phenotype were combined and stained with mouse monoclonal α-HA IgG followed by 
an Alexa Fluor 594-conjugated goat anti-mouse IgG secondary antibody. Fluorescence 
was detected using a Zeiss LSM 710 confocal microscope. 
 
When Bvg– phase colonies were stained, only green-fluorescing bacteria were 
observed and no red fluorescence was detected. When Bvgi phase colonies were stained, a 
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small proportion of cells displayed red or green fluorescence, but the majority of cells were 
not fluorescent and no bacteria displayed both red and green fluorescence (Figure 11). In 
contrast, when LCVs from RBX9BatB-HAfla-gfp were stained, approximately half of the 
bacteria fluoresced red and approximately half fluoresced green (Figure 11). No co-
localization of red and green fluorescence from either LCVs or Bvgi phase colonies was 
observed, confirming that the expression of vags and vrgs is mutually exclusive under these 
conditions. These data demonstrate that LCVs are composed of both Bvg+ and Bvg– phase 
bacteria and are not a homogeneous population of Bvgi phase bacteria. 
 
The ∆fhaB mutation in RBX9, but not lack of FHA protein, is responsible for the LCV 
phenotype. To determine if the generation of LCVs was due to lack of FHA protein 
production or the specific genetic architecture created by the ΔfhaB mutation in RBX9, we 
first determined if other fhaB mutants yielded LCVs. Strain RB50ΔPfhaB contains a deletion 
mutation of the fhaB promoter, strain RB50ΔSPfhaB contains a deletion mutation in fhaB such 
that the extended signal peptide of FHA is missing, and strain RB50ΔβhelixfhaB contains a 
large deletion mutation in the region of fhaB encoding the β-helix structure (Figure S17). 
These strains were analysed for FHA production by Western blot, and either produced no 
FHA protein (RB50ΔPfhaB and RB50ΔSPfhaB) or a severely truncated FHA protein 
(RB50Δβ-helix) (data not shown). We grew these strains under Bvg– phase conditions and 
plated single colonies onto Bvg+ phase conditions to determine if they would produce LCVs 
similar to RBX9. No LCVs were observed, suggesting that a lack of wild-type FHA protein 
is not sufficient to produce the LCV phenotype.  
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To investigate the contribution of the genetic architecture created by the fhaB deletion 
to the LCV phenotype, we created RB50::pBam, a strain that produces FHA and contains an 
altered fhaB-bvgAS locus (Figure S17). RB50::pBam was created by integrating pBam, a 
suicide plasmid containing the fhaB-bvgAS intergenic region, into the RB50 chromosome. 
Therefore, RB50::pBam has a complete fhaB ORF in addition to non-native plasmid DNA 5´ 
to the fhaB-bvgAS intergenic region. After modulation, RB50::pBam produced LCVs similar 
to RBX9. These data suggest that the LCV phenotype can be produced by altering the genetic 
architecture 5´ to the fhaB-bvgAS intergenic region and is independent of FHA production.  
 
The LCV phenotype results from a defect in bvgAS positive autoregulation. In addition 
to activating all of the known virulence factor-encoding genes in Bordetella, BvgAS 
activates bvgAS expression though positive autoregulation. Williams et al. demonstrated that 
positive autoregulation is required for the precise transition between and maintenance of the 
Bvg+, Bvgi, and Bvg– phases (35). Three observations suggested that LCVs resulted from 
defective bvgAS autoregulation in RBX9. First, the mutations that cause LCVs are 
genetically linked (immediately 5´) to bvgAS; second, LCVs consist of bacteria in least two 
separate BvgAS-controlled phenotypic phases; and third, LCVs were induced in vitro 
following a switch from Bvg– to Bvg+ phase growth conditions.  
We hypothesized that when RBX9 (or RB50::pBam) bacteria are switched to Bvg+ 
phase conditions from Bvg– phase conditions, most, like all wild-type bacteria, are able to 
activate transcription at the bvgAS P1 promoter, leading to increased BvgAS levels and 
resulting in the transition to and maintenance of the Bvg+ phase. According to our 
hypothesis, however, a small subset of RBX9 and RB50::pBam bacteria are unable to 
activate bvgAS transcription, possibly due to insufficient levels of BvgA and/or BvgS, and 
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these bacteria are therefore “trapped” in the Bvg– phase. We hypothesized further that 
although some descendants of these “Bvg– phase-trapped” bacteria will be able to activate 
bvgAS transcription and hence “escape” to the Bvg+ phase, many will remain Bvg– phase-
trapped and thus a substantial Bvg– phase population will be maintained in the LCV. An 
alternate hypothesis is that LCVs arise from spontaneous or transient shifting of bacteria 
between the Bvg+ and Bvg– phases, which would also result in a mixture of Bvg+ and Bvg– 
phase bacteria within a single colony. 
To determine if LCVs contain Bvg– phase-trapped bacteria, we used the recombinase-
based reporter system pGFLIP, which creates a permanent genetic change in response to 
gene activation (46). In this system, a promoter of interest drives expression of the site-
specific recombinase-encoding gene flp, which when activated, results in recombination 
between Flp recombinase target (FRT) sites that flank gfp and the kanamycin (Km) resistance 
gene nptII. Therefore, any activation (even transient, low-level expression) of flp results in a 
permanent loss of Km resistance and GFP fluorescence. This system targets the reporter 
construct to the neutral attTn7 site 3’ to glmS. We created strain RBX9cyaAFLP by mating 
the plasmid pGFLIP-PcyaA, in which the B. bronchiseptica cyaA promoter drives flp 
expression, into RBX9. The cyaA gene is exclusively controlled by BvgAS, is highly 
expressed in the Bvg+ phase, and is expressed minimally in the Bvg– phase (22). In 
RBX9cyaAFLP, bacteria that have never expressed cyaA should remain GFP+ and Kmr, 
whereas bacteria that have expressed cyaA should convert to GFP– and Kms. If gfp is lost due 
to PcyaA activation, all descendent cells will also be GFP– and Kms.  
Previously, we demonstrated that RB50cyaAFLP bacteria remain GFP+ under Bvg– 
phase conditions with Km selection and that they reach 100% resolution (GFP– cfu/total cfu) 
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when grown under Bvg+ phase conditions (46). When RBX9cyaAFLP was plated under Bvg– 
phase conditions with Km selection, each colony was morphologically identical and 
fluorescent, indicating that cyaA had not been activated to a level required for sufficient flp 
expression to lead to recombination between FRT sites (Figure 12A).  
In contrast, when a colony of RBX9cyaAFLP that was grown under Bvg– phase 
conditions was plated and grown under Bvg+ phase conditions, approximately 15% of the 
colonies were LCVs and approximately 80% of those LCVs were GFP+ (Figure 12B). None 
of the Bvg+ phase colonies were GFP+. When a GFP+ LCV was replated and grown under 
Bvg+ phase conditions, approximately 5% of the colonies were LCVs and approximately 
80% of those were GFP+ (Figure 12C). We serially replated GFP+ LCVs eight times and in 
all cases, additional GFP+ LCVs were generated (data not shown). These data indicate that a 
significant proportion of bacteria within a GFP+ LCV had never activated cyaA and had 
therefore failed to switch to Bvg+ phase in response to a change in conditions; i.e., they were 
Bvg– phase-trapped. Moreover, our data suggest that all LCVs arise from a Bvg– phase-
trapped bacterium and that upon subsequent multiplication, most descendants have “escaped” 
to the Bvg+ phase but a small proportion remain trapped in the Bvg– phase. These data do not 
support a model in which LCVs consist of bacteria that transiently fluctuate between Bvg+ 
and Bvg– phase, because if this was true, LCVs would not be GFP+. 
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Figure 12. LCVs from the strain RBX9PcyaAFLP are GFP+, indicating that cyaA has 
not been activated in a substantial proportion of these colonies. A, RBX9PcyaAFLP on 
BG blood agar + 50mM MgsO4 (Bvg– phase conditions); B, a GFP+ colony from A 
plated onto BG blood agar (Bvg+ phase conditions); C, a GFP+ LCV from B plated onto 
BG blood agar (Bvg+ phase conditions). Colonies were visualized after 48h of growth. 
 
Approximately 20% of the LCV colonies were GFP–, indicating that PcyaA-flp 
expression was sufficient to mediate recombination in the bacterium that founded the LCV or 
in its early descendants. Although this result appears inconsistent with our model, we have 
observed previously that when RB50cyaAFLP is grown under Bvg– phase conditions (when 
cyaA expression is minimal) and without Km selection, PcyaA-flp is expressed sufficiently in 
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approximately 15% of bacteria such that they convert to GFP– and KmS (46). These data 
indicate that the cyaA promoter activity under Bvg– phase conditions is near the threshold 
level required for flp expression and subsequent recombination. Therefore, GFP– LCVs are 
most likely due to the activity level of the cyaA promoter under Bvg– phase conditions and 
not due to bacteria switching to the Bvg+ phase and then back to the Bvg– phase. 
Nonetheless, our data indicate that in approximately 80% of LCVs, appear to have a defect in 
bvgAS positive autoregulation, leading to the observed Bvg− phasetrapped population. 
 
Sequences upstream of the fhaB-bvgAS intergenic region affect the efficiency of bvgAS 
activation in the Bvg– phase. Our data indicate that bvgAS autoregulation is defective in 
RBX9 and specifically, that LCVs are composed of a subpopulation of Bvg– phase-trapped 
bacteria. As stated in the introduction, bvgAS is controlled primarily by two promoters. 
Studies with B. pertussis have shown that under Bvg− phase conditions, P2 is transcribed at a 
low basal level. This level of transcription results in BvgS levels that are sufficient to respond 
to Bvg+ phase conditions by autophosphorylating and mediating phosphorylation of BvgA. 
The resulting BvgA∼P levels are sufficient to bind at the bvgAS P1 promoter, recruit RNAP, 
and activate transcription (38). (Although similar transcriptional analyses have not been 
conducted with B. bronchiseptica, the nucleotide sequence of the fhaB-bvgAS intergenic 
region in B. bronchiseptica is 91.1% identical and most of those differences are located in 
regions that, based on B. pertussis studies, are not bound by either BvgAS or RNAP.) We 
considered two hypotheses: 1) the level of transcription from P2 in RBX9 is lower than in 
RB50 such that in some bacteria the levels of BvgAS are too low to activate transcription at 
P1 in response to Bvg+ phase conditions, and 2) transcription activation at P1 by BvgA~P is 
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somehow defective in RBX9 compared to RB50. Moreover, our data suggest that defective 
autoregulation in RBX9 is due to the lack of native sequences or presence of non-native 
sequences 5´ to the fhaB-bvgAS intergenic region.  
 
 
Figure 13. Sequences upstream of bvgAS affect transcription efficiency under Bvg– 
phase conditions. A, Schematics of RB50PshortbvgAFLP and RB50PlongbvgAFLP showing 
the sequences 5´ to flp inserted at the attTn7 site (not drawn to scale); B and C, strains 
were first grown on BG blood agar + 50 mM MgSO4 + Km and one colony was plated 
onto BG blood agar + 50 mM MgSO4 (Bvg– phase conditions) without Km selection; D 
and E, strains were grown on BG blood agar + 50 mM MgSO4 + Km selection and then 
one colony of each was plated onto BG blood agar (Bvg+ phase conditions) without 
selection. Representative white light (left) and fluorescent (right) images are shown for 
panels B, C, D, and E. 
 
To test our hypotheses, we constructed RB50PshortbvgAFLP and RB50PlongbvgAFLP, 
where RB50PshortbvgAFLP contains only the fhaB-bvgAS intergenic region driving flp and 
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RB50PlongbvgAFLP contains this region plus an additional 1200 bp of fhaB sequences 
driving flp (Figure 13A). These strains were constructed under Bvg– phase conditions in the 
presence of Km. To investigate P2 expression, we determined the percent resolution (the 
percentage of cfu that had activated flp) of each strain grown under Bvg– phase conditions by 
counting the ratio of GFP– cfu to total cfu when one colony was plated from Bvg– phase 
conditions with Km selection to Bvg– phase conditions without Km selection. The average 
resolution under Bvg– phase conditions in RB50PshortbvgAFLP was 68% whereas the average 
resolution in RB50PlongbvgAFLP was 97%. Plates are shown from one representative 
experiment (Figure 13B, C). Our data indicate that the per-cell activation of 
RB50PshortbvgAFLP is lower than the per-cell activation of RB50PlongbvgAFLP under Bvg– 
phase conditions, and demonstrate that either a lack of native fhaB sequences or the presence 
of non-native sequences has a direct effect on the efficiency of bvgAS transcription in the 
Bvg– phase.  
When a colony from each strain was grown on Bvg– phase conditions with Km 
selection and then plated onto Bvg+ phase conditions without Km selection, maximum 
resolution was achieved and there were no GFP+ colonies in either strain (Figure 13D, E). 
These data suggest that RBX9 does not have a defect in transcription activation at P1. 
 
The LCV phenotype is caused by a (divergent) promoter in proximity to bvgAS. Based 
on our results, we hypothesized that sequences within fhaB (1-1200 nucleotides of the coding 
region) 5´ to the fhaB-bvgAS intergenic region effect the low level of transcription from P2 
that occurs under Bvg– phase conditions. To test this hypothesis, we constructed a strain 
containing a deletion mutation from nt 8 to 1256 of fhaB (Figure S17 C). This mutant did not 
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produce LCVs when switched from the Bvg– to the Bvg+ phase. We conclude that the lack of 
specific sequences within the first 1200bp of fhaB do not cause the LCV phenotype.  
 
Figure 14. The genetic architecture of the bvgAS-fhaB intergenic region of strains that 
do and do not produce LCVs. Strains that produce LCVs or demonstrate a defect in 
bvgA-flp activation have divergent promoters 5´ to the bvgAS-fhaB intergenic region. 
Schematics for RB50PshortbvgAFLP and RB50PlongbvgAFLP represent sequences 
inserted at the attTn7 site. Dotted lines represent non-coding plasmid DNA. Sequence 
lengths from the ATG of fhaB to the nearest 5’ ATG are indicated. Not drawn to scale. 
 
These data led us to closely reexamine the genetic architecture of each strain that 
produced LCVs (RBX9 and RB50::pBam) as well as the strains that showed a difference in 
bvgAS-flp reporter activation (RB50PshortbvgAFLP and RB50PlongbvgAFLP). A comparison 
of these strains revealed the presence of a divergent promoter 5´ to the fhaB-bvgAS intergenic 
region in RBX9, RB50::pBam, and RB50PshortbvgAFLP (Figure 14). In RBX9, the fimA 
promoter is very close to the fhaB-bvgAS intergenic region, in contrast to RB50 in which it is 
separated by the entire (>12kb) fhaB gene. In RB50::pBam, the bla promoter (driving 
expression of the ampicillin resistance gene on the plasmid) is adjacent to the fhaB-bvgAS 
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intergenic region. In the strain RB50PbvgAshortFLP, the npt promoter (driving expression of 
the kanamycin resistance gene on the plasmid) is proximal to PbvgA-flp, whereas the 
RB50PbvgAlongFLP reporter is “buffered” from the same npt promoter by an additional 
1200bp of fhaB (Figure 14). We hypothesized that the presence of a promoter 5´ to the 
bvgAS-fhaB intergenic region was interfering with bvgAS P2 transcription, possibly by 
sequestering RNA polymerase away from P2. To test the hypothesis that nearby promoters 
affect P2 transcription, we reversed the orientation of the insert in the plasmid pBam. In the 
resulting plasmid, pBamR, the bla promoter is no longer proximal to the bvgAS homology 
region. Instead, the closest promoter 5’ to bvgAS on the plasmid is the aaC1 promoter 
(driving expression of the gentamicin resistance gene), which is more than 1.5kb away 
(Figure 14). We created RB50::pBamR by integrating the pBamR plasmid into the RB50 
chromsome. Modulating RB50::pBamR and plating bacteria onto Bvg+ phase conditions 
resulted in all colonies having the typical Bvg+ phase morphology, and no LCVs were 
observed. The LCV phenotype was therefore abolished by changing the sequences upstream 
of the bvgAS-fhaB region, presumably by increasing the distance between a promoter and 
bvgAS. Additionally, we deleted the intergenic region between fhaB and fimA (which 
includes the fimA promoter) in RBX9. The resulting strain RBX9F did not produce LCVs 
after modulation. These data strongly support a model in which a promoter upstream of 
bvgAS interferes with normal P2 transcription efficiency, resulting in some cells having an 
insufficient quantity of BvgAS to activate transcription at P1. 
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Each Bvg– phase-trapped bacterium within an LCV initiates the formation of a new 
LCV and the proportion of Bvg– phase-trapped bacteria within an LCV decreases over 
time. Our data indicate that LCVs are founded by a single Bvg– phase-trapped bacterium and 
that each LCV harbors Bvg– phase-trapped bacteria that can propagate additional LCVs. 
However, it is unclear whether all Bvg– phase-trapped bacteria, or only a subset of these 
cells, yield LCVs upon replating. To address this question, we needed two pieces of 
information: the proportion of Bvg– phase-trapped bacteria within one LCV and the 
frequency of new LCV formation from the same parent colony when replated. We used 
RBX9cyaAFLP to evaluate the composition and LCV-forming capacity of single LCVs. 
Plating a GFP+ LCV onto Bvg– phase conditions, in which cyaA expression is 
minimal, will minimize further Flp-mediated recombination due to cyaA activation, 
permitting us to determine the proportion of GFP+ bacteria (and hence Bvg– phase-trapped) 
existing within the LCV at that time. Plating the same GFP+ LCV onto Bvg+ phase 
conditions will allow us to determine the number of new LCVs generated from the 
subpopulation of Bvg– phase-trapped bacteria in the parent LCV. Comparing the frequency 
of newly generated LCVs under Bvg+ phase conditions to the frequency of GFP+ cfu under 
Bvg– phase conditions will reveal the proportion of Bvg– phase bacteria that form LCVs 
when replated. 
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Figure 15. A, Schematic of RBX9cyaAFLP experimental design, including a data set 
from one replicate. Each pie chart represents the population obtained from plating a 
single GFP+ colony from the previous plate (see text for details). Blue sectors in pie 
charts represent the frequency of GFP– cfu; Green sectors in pie charts represent the 
frequency of GFP+ cfu; offset regions of pie charts represent the frequency of LCVs. B, 
Comparison of GFP+ cfu frequencies obtained from plating a single GFP+ LCV onto 
Bvg+ and Bvg– phase conditions. C, Comparison of GFP+ cfu frequencies obtained from 
plating a GFP+ LCV grown after 48h and 72h. Background color represents BvgAS 
conditions, where red is Bvg+ phase conditions and blue is Bvg– phase conditions. **, P 
= 0.005 by Student’s Unpaired T-test. 
 
We first grew RBX9cyaAFLP on Bvg– phase conditions with Km selection to 
maintain the gfp and Kmr markers (Figure 15A I). Then we took single GFP+ (Bvg– phase) 
colonies and plated them onto Bvg+ and Bvg– phase conditions (Figure 15A II). GFP+ LCVs 
that were recovered from Bvg+ phase plates were then plated again onto Bvg+ and Bvg– 
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phase conditions (Figure 15A III). The numbers of GFP+ cfu, LCVs, and Bvg+ phase colonies 
from each plate were recorded. The results from one representative experiment are shown in 
Figure 15A. When the GFP+ LCVs were plated onto Bvg+ and Bvg– phase conditions, there 
was no significant difference in the average number of GFP+ cfu under Bvg– phase 
conditions compared to the average number of GFP+ LCVs on the corresponding BG blood 
agar plate (Figure 15B). These data suggest that each Bvg– phase bacterium within an LCV is 
Bvg– phase-trapped and forms an LCV when replated onto Bvg+ phase conditions.  
Additionally, we asked if the composition of LCVs (i.e., the ratio of Bvg– to Bvg+ 
phase bacteria) changed over time. We hypothesized that this ratio would change due to 
bacterial division as well as the rate of conversion of Bvg– phase-trapped bacteria to Bvg+ 
phase bacteria. Because we expected a unidirectional conversion of phenotypes (Bvg– to 
Bvg+ phase only) under Bvg+ phase conditions, we predicted that the ratio of Bvg– to Bvg+ 
phase bacteria would decrease as the bacterial population increased. To determine if the 
compositions would change after an additional day of growth, we compared GFP+ LCVs 
plated after our standard incubation time (48h) (Figure 15A III) to GFP+ LCVs plated after 
72 h (Figure 15A IV). When GFP+ LCVs were plated after 48h of incubation, we obtained an 
average of 12 ± 1.2% GFP+ cfu under Bvg– phase conditions, whereas after 72h, we obtained 
an average of 5.75 ± 1% GFP+ cfu under the same conditions (P=0.005) (Figure 15C). These 
data indicate that the frequency of GFP+ (and therefore Bvg– phase-trapped) bacteria in an 
LCV decreases over time.  
These data also strongly suggest (as discussed in a previous result) that GFP– LCVs 
are a result of the background activation of cyaA in RBX9PcyaAflp, as the background cyaA-
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flp activation under conditions of inactivity (Bvg– phase conditions) was the same as the 
frequency of GFP– LCVs (to total LCVs) under Bvg+ phase conditions (Figure 15A II).  
 
Modulation of RBX9 in vivo occurs at a very low frequency. All data published thus far 
strongly suggest that wild-type Bordetella do not modulate to the Bvgi or Bvg– phase in vivo 
and that the Bvg+ phase is necessary and sufficient for infection (40–45). The recovery of 
LCVs from mouse lung homogenates and the fact that LCVs were recovered in vitro only 
following modulation, however, supports the hypothesis that RBX9 modulates during 
infection. To test this hypothesis, we constructed strain RBX9flaAFLP, a strain containing 
the pGFLIP cassette in which the flaA promoter drives expression of flp (46). Previously, 
using the same PflaA-flp-containing cassette in wild-type RB50, we showed that flaA was not 
activated to a detectable level in RB50 during murine infection (46). RB50flaAFLP and 
RBX9flaAFLP bacteria were grown under Bvg+ phase conditions with Km selection to 
minimize background resolution prior to inoculation. Mice were inoculated intranasally with 
7.5x104 – 1x105 cfu and lungs were harvested at 3, 24, 30, and 72 hours post-inoculation. We 
conducted this experiment several times. In all experiments, a low proportion (≤1%) of GFP– 
bacteria was recovered from the lungs of both RB50flaAFLP- and RBX9flaAFLP-inoculated 
animals (data not shown). This low proportion was not significantly different, however, from 
the proportion of GFP– bacteria present in the samples used for inoculation (plated after 
inoculating the animals). Data from previous work with RB50flaAFLP (46) and our 
experiments with RBX9flaAFLP indicate that resolution of the PflaA-flp cassette is BvgAS-
dependent because GFP– bacteria are never recovered from strains containing the bvgS-C3 
mutation, which locks the bacteria in the Bvg+ phase (data not shown). For the 
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RBX9flaAFLP-inoculated animals, most of the GFP– colonies recovered from the mouse 
lungs were LCVs and no GFP+ LCVs were recovered, indicating that formation of LCVs in 
vivo correlates with, and is most likely caused by, BvgAS modulation. Together, these data 
suggest that a very small proportion of RBX9 modulates to the Bvg– phase during infection. 
However, our data neither support nor refute the possibility that RB50 modulates as well. 
To determine if bacteria modulate to the Bvgi phase during infection, we attempted to 
construct strains with Bvgi phase promoters, including the bipA promoter, driving flp. 
However, we were unable to construct these strains, presumably because the level of 
expression of these genes in Bvg+ phase conditions was above the threshold of flp activation 
required for recombination and loss of GFP and KmR. 
 
If BvgAS modulation occurs in vivo, it does not alter the outcome of infection. Our data 
suggest that a small proportion RBX9 (and possibly RB50) bacteria may modulate to the 
Bvg– phase during infection. Although several previous experiments have shown that wild-
type and Bvg+ phase-locked B. bronchiseptica strains are indistinguishable in animal models 
(40–43, 45), we considered the possibility that the proportion of RBX9 bacteria that 
modulate in vivo could actually be greater than that of RB50, but not apparent from the PflaA-
flp data because modulated RBX9 bacteria are killed in the host (i.e., that modulated bacteria, 
and perhaps specifically modulated RBX9 bacteria are more susceptible to host-mediated 
clearance than modulated RB50 bacteria). To test this hypothesis, we compared RBX9, 
RBX9c (the Bvg+ phase-locked derivative of RBX9), RBX9F (the ∆PfimA derivative of RBX9 
which is not defective for bvgAS autoregulation), and RBX9cF (a Bvg+ phase-locked 
derivative of RBX9F) in mice. The results of three independent experiments are shown in 
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Figure 16. In no case did a statistically significant difference in bacterial burden occur 
amongst the various strains. These data negate our hypothesis and provide strong evidence 
that the low level of BvgAS modulation that occurs in vivo (based on the recovery of LCVs) 
does not impact the outcome of infection. 
 
Figure 16. Comparison of RBX9, RBX9c, RBX9F, and RBX9cF burdens in the mouse 
lung after 3h and 72h p.i. RBX9c and RBX9cF are Bvg+ phase-locked derivatives of 
RBX9 and RBX9F, respectively; four-to eight-week-old BALB/C mice were intranasally 
infected with 1×105 cfu in 50µl and lungs were harvested at each time point; each 
diamond or circle indicates the number of cfu recovered from a single animal and each 
horizontal line indicates the geometric mean for each group; these data represent three 
independent experiments with at least two mice per strain per time point. 
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Discussion 
The discovery and characterization of LCVs in B. bronchiseptica yielded several 
interesting findings, the most significant being evidence that transcriptional interference can 
result from activity at a promoter located several hundred nucleotides 5´ to the affected 
promoter. Given this relatively large distance between promoters, the mechanism of 
interference likely does not involve direct blocking of transcription; therefore, we suggest the 
name ‘passive transcriptional interference’ for this phenomenon. Our data indicate that the 
bvgAS P2 promoter is sensitive to passive transcriptional interference and that it results in the 
emergence of a bistable phenotype, apparent as LCVs, when bacteria are switched from Bvg– 
phase conditions to Bvg+ phase conditions. The fact that LCVs, which contain Bvg– phase-
trapped bacteria, were recovered from the lungs of infected mice, provided evidence that 
BvgAS modulation occurs in vivo. Our experiments indicate, however, that although a small 
proportion of bacteria may modulate during infection, this level of modulation does not alter 
the outcome of infection. 
Bacterial populations often exhibit phenotypic heterogeneity. A common mechanism 
by which bacteria can generate this heterogeneity is phase variation, a reversible and 
heritable change in phenotype (due to either genetic or epigenetic modifications) often 
manifested as different colony morphologies (52, 53). Phase variation frequently alters the 
production of surface-exposed epitopes such as pilli, capsule, flagella, lipopolysaccharide 
(LPS), and adhesins (52). Coincidently, phase variation is often associated with virulence and 
is an important strategy used by pathogens to avoid immune selection. Some well-
characterized examples of phase variation include the opa operon encoding adhesin proteins 
in Neisseria species, the pap operon encoding fimbrae in E. coli, and the flagella subunits 
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encoded by fljBA and fliC in Salmonella enterica serotype Typhimurium (54–56). In 
Bordetella, phase variation in both fim3 and bvgAS has been described (57, 58).  
More recently, a phenomenon that generates bistable populations at the single-cell 
level has been discovered, called feedback-based multistability (FBM) (59). FBM is distinct 
from phase variation in that it is not based on genetic mutations but is instead based on 
feedback loops of regulatory networks (59). In isogenic populations, these feedback networks 
can result in bistability, which occurs when individuals in a population exhibit either one of 
two alternative stable steady-states (but not intermediate states) (60). A well-characterized 
example of FBM is in Bacillius subtilis, in the regulation of competence orchestrated by the 
transcription factor ComK (61). Competence is a cellular state induced by nutrient depletion, 
but only occurs in a fraction of the B. subtilis population due to oscillating levels of ComK at 
the single-cell level (62, 63). In one study, Smits et al. removed the external regulation of 
comK, leaving only positive autoregulation, and showed that ComK levels continued to 
exhibit bistability. Therefore, the authors argue that ComK bistability can be reduced to a 
positive autoregulatory loop in concert with random transcriptional and translational 
fluctuations or “noise” (64). This claim is supported by other examples, in which feedback 
regulation and a non-linear input are the only required components for a bistable system (60, 
65).  
We discovered LCVs of B. bronchiseptica after plating lung homogenates of mice 
infected with strain RBX9 and found that they yielded a heterogeneous population upon 
restreaking onto BG blood agar. We did not find evidence of classical phase variation in 
RBX9. Instead, the mechanism by which LCVs are generated appears more similar to FBM, 
in which the concentration of BvgA under Bvg– phase conditions varies in the population and 
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results in only some bacteria committing to a positive feedback loop when switched to Bvg+ 
phase conditions. In support of this, we were able to label bacteria within LCVs with tags 
unique to the Bvg+ and Bvg– phase and demonstrate the existence of two phenotypically 
distinct populations (Figure 11). The dual-tagged RBX9 strain also provided the first direct 
evidence that Bvgi phase cultures are not simply a mixture of Bvg+ and Bvg– phase bacteria. 
Use of the recombinase-based reporter system pGFLIP (46) showed that the ∆fhaB 
mutation in RBX9 causes a decrease in the efficiency of bvgAS positive autoregulation and 
results in Bvg– phase-trapped bacteria that decline in proportion over time and can initiate the 
formation of new LCVs (Figure 12, 13, and 15). Based on these results and previous data, we 
postulate a model of LCV formation and propagation (Figure S18). According to our model, 
the concentration of BvgA varies in a population and also in individual cells as they grow 
and divide. In RB50, the average concentration of BvgA under Bvg– phase conditions is such 
that 100% of the bacteria are able to respond to Bvg+ phase conditions and transition to the 
Bvg+ phase phenotype (Figure S18 A,B). In RBX9 however, the average concentration of 
BvgA is decreased under Bvg– phase conditions compared to wild-type bacteria (curve 
shifted to the left in Figure S18A, such that a subpopulation is below the threshold level 
required to respond to Bvg+ phase conditions. These bacteria are thus Bvg– phase trapped and 
remain phenotypically Bvg– phase even under Bvg+ phase conditions. Under Bvg+ phase 
conditions, these bacteria form LCVs, which continue to harbor Bvg– phase-trapped bacteria. 
The Bvg– phase-trapped bacteria within LCVs occasionally escape to become Bvg+ phase 
descendants, possibly through unequal division or stochastic accumulation of BvgA (Figure 
S18C). Therefore, in this system, a mutation that decreases the basal concentration of the 
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positively autoregulated factor (BvgA) results in an FBM-like phenotype, whereas in other 
systems, FBM is the natural mechanism by which bacteria reach a bistable state.  
Our pGFLIP data indicated that the bvgAS positive autoregulation defect is due to 
decreased activity of P2. This result explains why RBX9 has lower levels of BvgA: it has 
decreased transcription of bvgAS. Our data suggest that the reason for decreased transcription 
is the presence of a promoter located 5´ to the P2 promoter. This upstream divergent promoter 
is exerting its negative effects on bvgAS from relatively far away (~800 bp) and appears to 
represent a previously undescribed form of transcriptional interference (the suppressive 
influence of one transcriptional process on another), (66). It is unclear whether this promoter 
must be highly active or divergently transcribed. However, as with other examples of 
transcription interference, we predict that increasing this promoter’s strength would also 
increase the degree of interference (67). Additionally, we predict that the orientation of the 
promoter may not be important and that reversing its orientation would not abolish 
interference if transcription read through was prevented. We do not understand 
mechanistically how this “passive” transcriptional interference occurs. One possibility is that 
the divergent promoter sequesters RNA polymerase away from the sensitive promoter (P2) or 
that transcription at this site influences DNA topology in a way that is prohibitive to P2 
activation. Although the LCV phenotype appeared as an artifact of genetic manipulation, our 
results are important as they demonstrate an undescribed form of transcriptional interference 
and also because they reveal a mechanism by which in-frame deletion mutations that can 
have unanticipated polar effects on neighboring genes. Furthermore, RBX9 and its 
derivatives constitute a genetically tractable system for studying additional mechanisms of 
transcriptional interference and details of FBM. 
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The LCVs also provided insight into the behavior of BvgAS during infection. The 
role of BvgAS-dependent modulation in the Bordetella life cycle is not completely 
understood and remains an important area of investigation. Several studies have attempted to 
determine if Bvgi or Bvg– phase bacteria exist at any point during Bordetella infection, and 
so far none have yielded positive results (40–43, 45). These data, together with those 
demonstrating that Bvg– phase bacteria transition rapidly to the Bvg+ phase following 
intranasal inoculation (46, 68), have led to the conclusion that not only is the Bvg+ phase 
necessary and sufficient for infection, but that bacteria switch to and remain in the Bvg+ 
phase in vivo. The Bvgi and Bvg– phases are hypothesized to be important for transmission 
and survival ex vivo, however, no role for these phenotypic phases in a natural setting has 
been demonstrated. For B. pertussis particularly, which appears to survive outside the host 
only briefly during transmission to a new host, the role of BvgAS modulation remains 
mysterious. The isolation of LCVs from mouse lungs provides strong evidence that at least 
some RBX9 bacteria modulate during infection. However, the proportion of bacteria that 
modulated and that could be recovered from the animals was very low. Because the PflaA-flp 
system was unable to reliably distinguish this low proportion of modulated bacteria from 
background resolution, we could not determine if wild type bacteria modulate in vivo. If they 
do not, our data would suggest that only FHA-deficient bacteria modulate in vivo, which 
would suggest that FHA functions to prevent the bacteria from experiencing a Bvg– phase 
environment during infection. In pilot experiments, we also recovered LCVs from mice 
infected with ΔfhaB, ΔcyaA double mutants – in higher proportions, in some cases, than in 
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mice infected with RBX9. These preliminary data suggest the intriguing possibility that FHA 
and ACT function together to prevent Bordetella from creating or entering a modulating 
environment in the host. Our future experiments will be aimed at testing this hypothesis. 
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Supplemental Information 
 
 
Figure S17. A, genetic architecture of strains that do and do not produce LCVs, 
including RB50∆PfhaB, RB50∆SPfhaB, RB50∆βhelixfhaB, and RB50::pBam with RB50 and 
RBX9 as a reference; B, schematic of pBam and pBamR plasmids and the orientation 
of their inserted sequences; blue dotted lines represent plasmid DNA; thick black lines 
represents fhaB-bvgAS intergenic region; C, Genetic architecture of strain 
RB50∆TPSfhaB; not drawn to scale.  
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Figure S18. A and B, Proposed distribution of BvgA concentration within populations 
of RBX9 and RB50. A, In the Bvg– phase, a proportion of RBX9 cells (shaded region) 
are Bvg– phase-trapped (i.e., have a concentration of BvgA below the threshold [dotted 
line] necessary to stimulate positive autoregulation upon transition to Bvg+ phase 
conditions). By contrast, all RB50 cells have a level of BvgA sufficient to initiate positive 
autoregulation upon transition to Bvg+ phase conditions. B, In the Bvg+ phase, the 
RBX9 cells that were below the threshold BvgA concentration in the Bvg– phase 
(shaded region as in A) maintain their low concentration of BvgA and are thus unable 
to switch to the Bvg+ phase. These cells are able to initiate LCV formation as described 
in C. Consistent with our in vitro data, all RB50 cells are able to switch to the Bvg+ 
phase. C, Model of LCV formation and propagation illustrated as a lineage diagram 
(see text for details). RBX9 bacteria exist as a heterogeneous population under Bvg– 
phase conditions, with some bacteria (white) being below the threshold of BvgA 
required to initiate positive autoregulation and others above this threshold (gray). 
When bacteria are switched to the Bvg+ phase, the Bvg– phase trapped bacteria form 
LCVs, whereas the other bacteria transition into the Bvg+ phase (black) and form Bvg+ 
phase colonies. Occasionally, Bvg– phase-trapped bacteria “escape” and can transition 
into the Bvg+ phase (indicated by gray cells between white and black cells), resulting in 
LCV formation after 48h. 
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Table S4 Strains and Plasmids used in this study 
 
Strain or Plasmid Description Reference 
Strains   
 E. coli   
  DH5α Molecular cloning strain (1) 
  RH03 Conjugation strain; Kms, DAP auxotroph (2) 
 Bordetella   
  RB50 Wild-type B. bronchiseptica strain; Smr (3) 
  RBX9 RB50 with an in-frame deletion mutation 
of fhaB  
(4) 
  RB53 RB50 with the bvgS-C3 mutation (Bvg+ 
phase-locked) 
(3) 
  RB50i RB50 with the bvgS-I1 mutation (Bvgi 
phase-locked) 
(5) 
  RBX9i RBX9 with the bvgS-I1 mutation (Bvgi 
phase-locked) 
(5) 
  RBX9c RBX9 with bvgS-CS3 mutation (Bvg+ 
phase-locked) 
This study 
  RB50::pBam RB50 with pBam integrated between 
bvgA and fhaB; Gmr 
This study 
 
  RB50::pBamR RB50 with pBamR integrated between 
bvgA and fhaB; Gmr 
This study 
  RB50∆fhaB RB50 with same ∆fhaB mutation as 
RBX9 
This study 
  RBX9BatBN-HAflaA-gfp RBX9 with N-terminal HA-encoding tag 
in batB (proceeding codon 55) and PflaA 
gfp at attTn7 
This study 
  RB50∆PfhaB RB50 with a deletion mutation of the fhaB 
promoter (nt -244 through -28 relative to 
the ATG) 
This study 
  RB50∆SPfhaB RB50 with a fhaB signal peptide deletion 
mutation (codons 2-70) 
This study 
  RB50∆βhelixfhaB RB50 with an in-frame deletion mutation 
of codons 385 -1979 of fhaB (encoding 
the β-helix) 
This study 
  RB50∆TPSfhaB RB50 with a deletion mutation of bp 8 -
1256 (within codons 3 - 413) in fhaB 
This study 
  RBX9cyaAFLP RBX9 with flp driven by PcyaA integrated 
at attTn7 
This study 
  RB50PshortbvgAFLP RB50 with flp driven by PbvgA-short 
integrated at attTn7 
This study 
  RB50PlongbvgAFLP RB50 with flp driven by PbvgA-long 
integrated at attTn7 
This study 
  RBX9F RBX9 with a deletion mutation of the This study 
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fimA-fhaB intergenic region 
  RBX9cF RBX9∆PfimA with the bvgS-CS3 mutation This study 
   
   
Plasmids   
 pSS4245 pBR322-based allelic exchange plasmid; 
Apr, Kmr 
(1) 
 pEG7S Bordetella allelic exchange vector; Apr, 
Gmr 
(7) 
 pEG7 pBR322-based suicide plasmid; Apr, Gmr (5) 
 pEG3SO Suicide plasmid encoding bvgS-CS3 
mutation (R570H) with flanking sequence 
(3) 
p∆PfhaB  pEG7S derivative with nt (-29) – (500) 
and (-750) – (-243) relative to fhaB ATG 
This study  
p∆SPfhaB pEG7S derivative with sequences 
comprising codons 30 of bvgA to codon 1 
of fhaB and codons 71-238 of fhaB 
This study 
p∆βhelixfhaB pSS4245 derivative with codons 218-235 
and 1979-2146 of fhaB 
This study 
p∆TPSfhaB pSS4245 derivative with sequences from 
codon 3 of fhab through codon 30 of bvgA 
and codons 413-567 of fhaB 
This study 
pX9∆PfimA  pSS4245 derivative with codons 1-183 of 
fimA and 16 bp 3’ to the fhaB STOP 
codon through codon 30 of bvgA of RBX9 
This study 
pGFLIP Tn7-based vector with PS12-gfp and nptII 
flanked by FRT sequences and flp 3’ to 
the MCS; Apr, Kmr (conditional) 
(8) 
pGFLIP-PcyaA pGFLIP with flp driven by the RB50 cyaA 
promoter, Apr, Kmr (conditional) 
(8) 
pGFLIP-PflaA pGFLIP with flp driven by the RB50 flaA 
promoter, Apr, Kmr (conditional) 
(8) 
pGFLIP-PbvgA-short pGFLIP with flp driven by the fhaB-
bvgAS intergenic region 
This study 
pGFLIP-PbvgA-long pGFLIP with flp driven by sequences 
1200bp of fhaB to the bvgAS translational 
start site 
This study 
pTnS3 Tn7 transposase expression vector 
containing tnsABCD; Apr 
(9) 
pBam pEG7 plasmid with bvgAS-fhaB intergenic 
region in the MCS 
This study 
pBamR pEG7 plasmid with bvgAS-fhaB intergenic 
region (reverse orientation relative to 
pBam) 
This study 
pUC18Tn7-flaA-gfp Tn7-based vector with PflaA-gfp; Apr, Kmr This study 
pUC18T-mini-Tn7T-Km-FRT Mobilizable transposition vector; Apr, (9) 
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Kmr 
pCW103 pSS4245 derivative with HA-encoding 
sequence flanked by batB sequences nt (-
300 from ATG)  to codon 55 and codons 
56-216. 
This study 
 
Strain Construction. Allelic exchange was done using derivatives of pEG7S or pSS4245 
according to (1, 10). All strains were confirmed by PCR and nucleotide sequence analysis. 
 
RB50∆fhaB was created by performing allelic exchange on RB50 using plasmid p∆fhaBnew.  
 
RBX9BatBN-HAflaA-gfp was created by first performing allelic exchange on RBX9 using 
plasmid pCW103. To the resulting strain, the miniTn7-flaAgfp construct was delivered via 
tronsposase-mediated insertion. 
 
RB50∆PfhaB was created by performing allelic exchange on RB50 using plasmid p∆PfhaB. 
 
RB50∆SPfhaB was created by performing allelic exchange on RB50 using plasmid p∆SPfhaB. 
 
RB50∆βhelixfhaB was created by performing allelic exchange on RB50 using plasmid 
p∆βhelixfhaB. 
 
RB50::pBam was created by introducing plasmid pBam into RB50 by conjugation and 
selecting co-integrants on BG Sm Gm agar as described by Akerley et al. 1995. 
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RB50::pBamR was created by introducing plasmid pBamR into RB50 by conjugation as 
described for RB50::pBam. 
 
RBX9cyaAFLP was created by delivering pGFLIP-PcyaA construct into the RBX9 
chromosome via transposase-mediated insertion and selecting on BG Sm Km + 50mM 
MgSO4. 
RBX9flaAFLP was created by delivering pGFLIP-PflaA construct into the RBX9 chromosome 
via transposase-mediated insertion and selecting on BG Sm Km. 
 
RB50PshortbvgAFLP was created by delivering pGFLIP-P-shortbvgA construct into the RB50 
chromosome via transposase-mediated insertion and selecting on BG Sm Km + 50mM 
MgSO4. 
 
RB50PlongbvgAFLP was created by delivering pGFLIP-P-long bvgA construct into the RB50 
chromosome via transposase-mediated insertion and selecting on BG Sm Km + 50mM 
MgSO4. 
 
RB50∆TPS was created by performing allelic exchange on RB50 using plasmid p∆TPSfhaB. 
 
RBX9F was created by performing allelic exchange on RB50 using plasmid p∆PfimA. 
 
RBX9c was created by performing allelic exchange on RBX9 using plasmid pEG3S0 
according to Cotter et al 1994. 
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RBX9cF was created by performing allelic exchange on RBX9F using plasmid pEG3SO. 
JS20c was created by performing allelic exchange on JS29 using plasmid pEG3SO. 
 
Plasmid Construction. All plasmids were confirmed by PCR and nucleotide sequence 
analysis. 
p∆fhaBnew was created by PCR amplifying the 1kb region flanking the in-frame deletion of 
fhaB of RBX9 and ligating this insert into the MCS of pSS4245. 
 
p∆PfhaB was created by PCR amplifying one fragment (corresponding to nt -574 through -244 
relative to the fhaB ATG) ligated to another fragment (corresponding to nt -28 through 470) 
of RB50 and ligating this ~1kb insert into the MCS of pSS4245. 
 
p∆SPfhaB was created by PCR amplifying one 500bp fragment (corresponding to codon 30 of 
bvgA to codon 1 of fhaB) ligated to another 500bp fragment (corresponding to codons 71-238 
of fhaB) of RB50 and ligating this ~1kb insert into the MCS of pEG7S. 
 
p∆βhelixfhaB was created by PCR amplifying one 501 bp fragment (corresponding to codons 
218-385 of fhaB) ligated to another 501 bp fragment (corresponding to codons 1979-2146 of 
fhaB) of RB50 and ligating this ~1kb insert into the MCS of pSS4245. 
 
p∆TPSfhaB was created by PCR amplifying one 460 bp fragment (corresponding to nt within 
codons 413-567 of fhaB) ligated to another 523 bp fragment (corresponding to nt within 
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codon 3 of fhaB to codon 30 of bvgA, including 426bp of intergenic region) from RB50 and 
ligating this ~1kb insert into the MCS of pSS4245. 
 
pX9∆PfimA was created by PCR amplifying one 550 bp fragment (corresponding to codons 1-
183 of fimA) ligated to another 500 bp fragment (corresponding to 16 bp 3’ to the fhaB STOP 
codon through codon 30 of bvgA ) of RBX9 and ligating this ~1kb insert into the MCS of 
pSS4245. 
 
pBam was created by PCR amplifying the fhaB-bvgAS intergenic region (corresponding to 
the 426 bp between each ATG) of RBX9 and ligating this fragment into the MCS of pEG7. 
 
pBamR was created by digesting pBam with BamHI (where BamHI cut sites flanked the 
insert), ligating, and screening transformed clones for the reverse orientation relative to 
pBam. 
 
pGFLIP-PbvgA-short was created by PCR amplifying the fhaB-bvgAS intergenic region (426bp) 
from RB50 and inserting this fragment into the MCS of pGFLIP with the bvgAS promoters 
driving flp. 
 
pGFLIP-PbvgA-long was created by PCR amplifying a 1626 bp fragment including nt 
corresponding to codon 400 of fhaB through the ATG of bvgA in RB50 and inserting this 
fragment into the MCS of pGFLIP with the bvgAS promoters driving flp. 
 
113 
miniTn7-flaAgfp was created by PCR amplifying 500 nt 5’ to the flaA ATG in RB50 and 
ligating this fragment into the MCS of pUC18T-miniTn7T-Km. To the resulting plasmid, we 
ligated sequences encoding promoterless gfp from miniTn7T-kan-gfp pUC such that the flaA 
promoter drives gfp. 
 
pCW103 was created by PCR amplifying sequence encoding an HA-tag flanked by 
homology region from batB including -300 nt from ATG to codon 55 and codons 56-216 and 
ligating this insert into the MCS of pSS4245. 
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CHAPTER 4: Conclusion 
 
Pertussis remains one of the most common vaccine-preventable diseases. Although 
widespread vaccination and antibiotic usage have dramatically reduced the burden of 
Bordetella disease, these bacteria still proliferate in carrier and unvaccinated populations. 
The recent resurgence of pertussis is now a driving force to improve the current acellular 
vaccine, understand its shortcomings, and learn more about Bordetella pathogenesis. Despite 
almost a hundred years of research, our understanding of the factors that affect Bordetella 
disease progression, the development of host protective immunity, and the bacterial life cycle 
is incomplete. 
Why is Bordetella virulence gene regulation interesting and how is it relevant to 
preventing and treating Bordetella disease? The Bordetella are unique pathogens with several 
phenotypic profiles that are controlled by a single, pervasive regulatory system, 
indispensable for virulence. BvgAS evolved to become the pinnacle of Bordetella sensory 
systems; dramatically changing the cell’s physiology in response to a gradient of stimuli. 
Understanding BvgAS has simplified the identification and characterization genes required 
for pathogenesis. From an evolutionary perspective, we know that B. pertussis became more 
virulent and specifically adapted to its host through reductive evolution and alterations in 
gene regulation; not by gene acquisition. Therefore, understanding BvgAS, its natural 
signals, its evolution, and its complete regulon, is indispensable to understanding Bordetella 
116 
pathogenesis. The experiments presented in this dissertation have sought to explore 
Bordetella virulence by understanding the subtleties of BvgAS-mediated gene regulation. 
One of the greatest mysteries of Bordetella and BvgAS is the role of modulation to 
the Bvgi and Bvg– phases. Especially for B. pertussis, the most fastidious of the B. 
bronchiseptica cluster, it is unclear why many of the vrgs remain intact. As an obligate 
human pathogen that cannot survive naturally outside of a host, transition out of the Bvg+ 
phase seems unnecessary, if not detrimental. In B. bronchiseptica, the Bvg– phase permits 
survival under nutrient-limiting conditions, and, is likely the dominant phase while the 
bacteria occupy ex vivo niches. For B. pertussis, the Bvg– phase has been proposed as an 
evolutionary remnant. However, the vrgs of each subspecies are diverse and thus appear to 
have evolved independently, suggesting distinct and important functions. For example, the 
vrgs encoding outer membrane proteins in B. pertussis are unique (by regulation), and 
therefore may perform alternate functions (or at least be required in a different context) 
distinct from the homologues in B. bronchiseptica. Additionally, the Bvg+ phase-locked 
phenotype can be accomplished through a single nucleotide mutation in bvgS. If the Bvg+ 
phase was necessary and sufficient for the entire lifecycle of B. pertussis, one would expect 
these mutations to appear frequently, although this is not observed. For B. bronchiseptica 
however, our experiments support previous data suggesting that modulation to the Bvg– 
phase does not occur during lung infection.  
Understanding in vivo gene expression has always been a prominent goal for studying 
pathogens; Bordetella is no exception. We designed a sensitive system, called pGFLIP, that 
can function as an in vivo reporter of gene activation in Bordetella. pGFLIP utilizes the site-
specific recombinase gene flp, driven by a promoter of interest. Upon production of Flp (and 
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thus activation of the promoter), the gfp and nptII (kmR) genes are permanenty excised. 
Utilization of this system to detect in vivo gene expression is straightforward if promoter-
inactive conditions are known: animals are infected with GFP+ bacteria, which are later 
recovered and screened for loss of GFP. The main drawback of pGFLIP is that the readout is 
negative: detecting a loss of signal (fluorescence) is more difficult than detecting a gain of 
signal. To overcome this problem, we are enhancing pGFLIP with a constitutive rfp gene, 
which will permit the visualization of every cell, such that cells with activated promoters will 
fluoresce distinctly. This new system, pRGFLIP, will be informative in conjunction with 
flow cyotmetry- and microscopy-based assays. 
pGFLIP was originally validated using Bordetella, and revealed unexpected 
differences in virulence gene regulation. In B. bronchiseptica, we showed that cyaA, 
characterized as a late Bvg+ phase gene in B. pertussis, was expressed considerably earlier 
when bacteria were switched from the Bvg– to the Bvg+ phase. This difference was not 
accounted for by the species-specific cyaA promoters or the bvgAS loci. We also showed that 
flaA was not expressed to a detectable level within the murine lungs during infection, 
supporting the hypothesis that the Bvg– phase does not play a role in vivo. These experiments 
demonstrate that pGFLIP is valuable as both an in vitro and in vivo reporter tool. 
pGFLIP was also instrumental in the characterization of LCVs, affectionately known 
as “wonkies,” in B. bronchiseptica. The discovery of wonkies from RBX9 provided insight 
into BvgAS regulation as well as general bacterial transcription processes. Wonkies 
recovered from animals suggested that modulation to the Bvg– phase occured in vivo, but as 
we later found out, had a negligible impact on infection. Interestingly, the mechanism by 
which wonkies are generated involves transcriptional interference of bvgAS. We term it 
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“passive” transcriptional interference because the distance between affected promoters is so 
great (≥800 bp) that physical blockage by RNAP is extremely unlikely. Wonkies are also 
interesting because they represent a bacterial population consisting of transiently Bvg– phase-
trapped bacteria and wild-type Bvg+ phase bacteria. This phenomenon suggests that bistable 
phenotypes can emerge by subtle alterations of transcription in a positively autoregulated 
system. 
We hope that these and other studies will someday contribute to the eventual 
eradication of Bordetella disease. Understanding BvgAS is fundamental to this goal.  
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APPENDIX A: Attempts to Create a Permanently Surface-Attached FHA Molecule in. B 
bronchiseptica 
 
The purpose of these experiments was to create a B. bronchiseptica mutant that 
produced and secreted FHA in a wild-type manner but remained attached to the cell surface; 
i.e., an FHA that was not released. This strain would be used to investigate and distinguish 
the functions of the surface-associated and released forms of FHA. We took three approaches 
to accomplish this: 1, we created mutants that contained deletions of sequences encoding a 
large portion of the β-helical subdomain, hypothesized to provide the energy for secretion; 2, 
we created mutants containing several double cysteine mutations in an attempt to stall 
secretion though disulfide bond formation in the periplasm; and 3, we created a mutant 
containing a deletion of sequences encoding 22 residues in FHA predicted to be the 
secondary protease (SphB1-independent) cleavage site. None of the mutations were 
sufficient to inhibit FHA secretion into the supernatant under any of the conditions tested. 
The energy source that drives all Type V Secretion exoproteins (including TPS and 
autotransporter systems) through the outer membrane remains unknown (1). Interestingly, 
almost all of these systems are predicted to contain β-helical structure (2–4). A popular 
hypothesis is that the sequential folding of a β-helical domain through the TpsB pore drives 
secretion of the rest of the TpsA molecule (3). To test this hypothesis and to determine if the 
β-helical domain was required for secretion, we deleted the majority of the sequences 
encoding the β-helical shaft domain of FHA, including approximately 1600 aa residues C-
terminal to the conserved TPS domain but N-terminal to the MCD. Although the TPS 
domain (including the first ~250 residues of the N-terminus) also folds into β-helical 
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structure, it is indispensable for recognizing FhaC and initiating secretion (5–7), and was 
therefore kept intact in our studies.  
We hypothesized that FHA lacking the majority of the β-helical shaft would become 
trapped within FhaC due to an absence of energy for the secretion of the globular MCD. Two 
strains were constructed: RBX20::pEM1, a Campbell-type integration that created an in-
frame deletion mutation of sequences encoding residues 385-1979 with a stop codon 
following the MCD domain, and RBX11∆β-helix, containing a clean in-frame deletion 
mutation of residues 285-1979 only. The primary difference between these strains is the 
presence of the prodomain, which affects the folding of FHA but is not required for release. 
We were unsure of the contribution of the prodomain to the secretion of these mutants.  
To our surprise, neither of these strains produced FHA that was incapable of release, 
as visualized by western blot analysis of supernatants (Figure 19). In addition, when the same 
∆β-helix mutations were introduced into a ∆sphB1 background, the release of cleaved FHA 
was just as prominent (although the slightly larger 90 kD form is dominant in the RBX11∆β-
helix∆sphB1 sample.) Although unexpected, one possible explanation is that the folding of 
the β-helical structure in the TPS domain is sufficient for FHA secretion, regardless of the 
absence of additional β-helical length. Another possibility is that the β-helix structure does 
not provide energy for folding and thus is not required for secretion of the MCD. Whichever 
is the case, it is clear that none of these mutations are sufficient to prevent release of FHA 
into the supernatant. 
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Figure 19. Western blots of strains containing deletion mutations of the β-helical shaft 
domain of FHA, compared to wild-type and ∆sphB1 derivative strains. A, Blot showing 
whole cell lysates (WCL) and supernatants (supe) of RB50, RBX11∆β-helix, and 
RBX11∆β-helix∆sphB1 probed with α-MCDFHA (rabbit) primary antibody and α-rabbit 
800λ secondary; The processed FHA fragment is approximately 90 kD (indicated by * 
on right of each blot), with another ~80kD (indicated by ~) form in the sphB1+ 
background. B, Blot showing WCL and supes of RB50, RBX9∆fhaB, RBX20::pEM1, 
and RBX20::pEM1∆sphB1; mature FHA fragments are approximately 90 kD; 
antibodies are same as in A; molecular weight marker (red) is shown on left in kD.  
 
Our second approach was inspired by other TPS systems that have evolved specific 
mechanisms for the surface retention of the TpsA exoprotein; namely, HMW1-type proteins. 
These proteins have two conserved cysteine residues near the C-terminus which form a 
disulfide bond in the periplasm, resulting in a stable plug that prevents release from the cell 
surface (8, 9). We hypothesized that by adding cysteine residues to FhaB, we could stall 
secretion through the same mechanism, as was done previously with pertactin (10), an 
autotransporter in Bordetella. Because FhaB has no natural cysteines, creating the mutations 
was straightforward. Several cysteine pair mutations were constructed within the TPS, β-
helical, and MCD domains that were separated by intervals ranging from ten to several 
thousand residues. We hypothesized that if any of the mutant pairs stalled secretion, it would 
suggest that the two regions were in the periplasm and in close proximity at some point 
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during the secretion process. Therefore, in addition to creating a strain that could not be 
released, we could also learn about the localization of each region of FhaB during secretion. 
 
 
Figure 20. Western blots of strains containing cysteine pair mutations in fhaB, 
compared to wild-type strains, probed with α-MCDFHA (green) and α-cyaA (red). A, B, 
and C, Blots showing whole cell lysates and supernatants of strains indicated; RBX11 
(∆fhaS) and RB50 are wild-type controls; molecular weight indicator is on the left of 
each blot in kD; FhaB is approximately 350 kD whereas FHA is approximately 250 kD 
(indicated by * on right of each blot). 
 
Figure 20 shows western blots of a wide panel of double cysteine mutation strains. 
Strains in the JS20 background were created via Campbell-type integration, whereas the 
others were created by using allelic exchange in the RBX11 (∆fhaS) background. All of the 
strains produced FHA that was secreted into the supernatant (although RBX11 D1674C 
Q72C appears to have significantly reduced secretion (Figure 20A), this result was 
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inconsistent in subsequent blots, where typical amounts of FHA were detected). The ability 
of all of the strains to secrete FHA was unexpected, but indicates that none of the cysteine 
pair mutations were sufficient to halt secretion through FhaC. It is particularly surprising that 
some strains, such as RBX11 Q72C Q81C and RBX11 S777C S786C, which contain 
cysteines only ten residues apart (and equivalent to the cysteine spacing found in HMW1), 
did not form a disulfide bond that inhibited secretion through FhaC. Two possibilities could 
account for these results: 1, none of the cysteine pairs formed disulfide bonds or 2, disulfide 
bonds formed but were insufficient to stall secretion in this specific context. In HMW1, it is 
known that the TpsA protein remains closely associated with the TpsB pore, which forms a 
dimer on the cell surface (9). It is possible that specific sequences within HMW1B (the TpsB 
protein) are required for this anchoring. 
Our third approach to creating a surface-attached FHA molecule was to target the 
SphB1-independent protease cleavage site. On the cell surface, SphB1 targets the PFLETRIK 
aa sequence in FhaB, and separates the MCD from the prodomain (11, 12). Previous attempts 
to prevent cleavage by deleting the sequences encoding the SphB1 cleavage site in fhaB were 
unsuccessful, indicating SphB1’s level of sequence promiscuity. Additionally, deletion of 
sphB1 itself does not prevent cleavage of FhaB, because another unidentified protease 
cleaves FhaB 5´ to the SphB1-recognition site (11, 13). Because we did not know the identity 
of the SphB1-independent protease, we predicted the location of its cleavage site based on 
experiments by Mazar and Cotter (11), and attempted to remove it. 
We hypothesized that deletion of the SphB1-independent cleavage site would prevent 
cleavage (and possibly release) of FhaB in a ∆sphB1 background. We created the strain 
RBX11∆22, containing an in-frame deletion mutation of the sequences encoding residues 
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2526-2547 in fhaB, predicted to be the SphB1-independent cleavage site. We also created 
strain RBX11∆β-helix∆sphB1∆22, since we know that in RBX11∆β-helix∆sphB1 the 
processed FHA is released as a much smaller (~90kD) form (Figure 19). Neither of these 
mutations prevented the SphB1-independent cleavage event nor the release of FHA into the 
supernatant (Figure 21). It is likely that the residues 2526-2547 were predicted incorrectly as 
the SphB1-independent cleavage site. Alternatively, this protease may also be promiscuous. 
The future identification of the SphB1-independent protease will likely be more successful in 
engineering an unprocessed FHA molecule. 
 
Figure 21. Western blots of ∆22 strains probed with α-MCDFHA (green) and in A, α-
cyaA (red). A and B, whole cell and supernatant preps of strains indicated; matured 
FHA is ~250kD (A) and ~90kD (B), indicated by * on the right of each blot 
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Table 5. Strains and plasmids used in this study 
 
Strain or Plasmid Description 
Strains  
RBX11∆22 RBX11 with a deletion of the sequences for codons 2526-2547 in fhaB 
RBX11∆βhelix RBX11 with a deletion of the sequences for codons 385-1979 in fhaB 
RBX21::pEM1 RBX20 with pEM1 cointegrated within the fhaB locus 
RBX11∆βhelix∆21pro∆S
phB1 
RBX11 containing deletion mutations of 2526-2547 
and 385-1979 in fhaB as well as ∆sphB1 
RBX11 D1674C S777C RBX11 with mutations that encode cysteines at residues 1674 and 777 of fhaB. 65/29 
RBX11 S777C Q72C RBX11 with mutations that encode cysteines at residues 777 and 72 of fhaB 65/35 
RBX11 Q72C Q81C RBX11 with mutations that encode cysteines at residues 72 and 81 of fhaB 65/44 
RBX11 S777C S977C RBX11 with mutations that encode cysteines at residues 777 and 977 of fhaB 65/53 
RBX11 S777C A786C  RBX11 with mutations that encode cysteines at residues 7774 and 786 of fhaB 5/57 
JS20 Q72C::G2132C 
JS20 with mutations that encode a cysteine at 
residue 72 as well as a plasmid cointegrated 
containing mutations that encode a cysteine at 
residue 2132 of fhaB. 
Plasmids  
pEM1 
pEG7 derivative containing flanking sequences of 
codons 385-1979 in fhaB followed by a STOP codon 
at residue 
pTPS-MCD pSS4245 derivative containing flanking sequences of codons ∆385-1979 in fhaB 
p∆22 pSS4245 derivative containing flanking sequences of codons ∆2526-2547 in fhaB 
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APPENDIX B: Characterization of the folding properties of the β-helix subdomain in B. 
bronchiseptica FHA 
 
These experiments were done in collaboration with Dr. Omar Saleh at the University 
of California, Santa Barbara, and their data are reprinted here with permission. The purpose 
of these experiments was to assess the physical properties of the β-helix subdomain in FHA 
and to characterize the energetics of folding of this common but poorly understood structure 
(1). With this goal in mind, we overexpressed and purified several 50 kD FHA fragments 
corresponding to different β-helical domains (repeat and non-repeat regions) (2). These 
fragments were engineered to contain unique N and C-terminal tags (Cysteine and 6xHis, 
respectively) for tethering. Dr. Saleh and colleagues characterized the properties of the FHA 
fragments using magnetic tweezers, whereby single molecules can be manipulated and 
observed (3). In this assay, each molecule is tethered to a surface by a magnetic bead. 
Tension is created by applying a stable and constant force to the fragment, while the length 
of the fragment is measured. Folding and unfolding dynamics of molecules can therefore be 
observed through changes of the molecule length (3).  
Five expression plasmids (using the pET21a vector, which contains a 6xHis tag) were 
constructed for the over-expression of different structural domains in FHA: four containing 
sequences encoding β-helix structure and one containing sequences within the MCD (Figure 
22). These constructs contain approximately 1500 nt corresponding to different sub-domains 
and repeat domains within the β-helix (excluding the MCD construct) that were identified by 
Kajava et al (4). The first fragment to be purified and analyzed was R1/CR3; later, the R1, 
R2, CR3, and MCD constructs were engineered. For unknown reasons, the R1 and R2 
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constructs could not be induced and therefore were not analyzed. So far, only data for the 
R1/CR3 fragment has been collected (Figure 24). 
 
 
Figure 22. Schematic of the fhaB gene including the domains Signal Sequence (SS) and 
Two-Partner Secretion domain (TPS) (red), β-helical shaft (blue), Mature C-Terminal 
Domain (MCD) (green), and prodomain (orange); Schematic of each fhaB sequence 
fragment constructed for overexpression in this study (arrows). 
 
A summary of the standard process of purification using nickel-affinity 
chromatography is as follows: constructs were induced in E. coli BL21* cultures by IPTG, 
cells were lysed, and lysates were bound to a column of nickel resin (via 6xHis), washed, and 
eluted (using ProBond resin, Invitrogen). Several steps of this process are visualized in the 
Coomassie-stained SDS-PAGE gel in Figure 23. The most concentrated elution fractions 
were then dialyzed, and sent to Dr. Saleh for analysis. 
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Figure 23. SDS-PAGE gel stained with Coomassie Blue showing various fractions in the 
process of purification of the R1/CR3 FHA fragment (approximately 48kD) using 
BL21:pET21aR1/CR3. From left to right: molecular weight ladder, shown in kD, 
uninduced culture, IPTG-induced culture, and elution fractions 1-6. Fractions 2 and 3 
were subsequently dialyzed for further purification. 
 
Saleh and colleagues observed equilibrium unfolding and refolding of the primary 
fragment, R1/CR3, in multiple discrete steps, supporting the hypothesis that the β-helix 
domain folds in a processive and vectorial manner (Figure 24). Surprisingly, the folding 
could not be modeled by a Brownian Ratchet system (5), which was hypothesized to account 
for unidirectional folding across the outer membrane (Dittmer and Saleh, unpublished 
results). Additionally, folding was observed as being distributed rather than cooperative, 
meaning that folding could nucleate at multiple locations and that numerous intermediate 
states existed. Additional work will be required to fully understand the β-helix structure 
contribution to the dynamics of FHA folding and secretion. One obvious caveat to this 
system is that natural folding of FHA may require the context of the complete FhaB protein 
(the prodomain may function as a chaperone (6)) as well as the interaction with FhaC and its 
specific pore environment. Therefore, we must use caution when interpreting these 
preliminary results.  
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Figure 24. Force traces of the FHA R1/CR3 fragment using magnetic tweezers showing 
length of molecule (nm) versus time (s); A, rapid reduction of force (force quench) from 
25pN to 5pN reveals the complete folding of the protein fragment and several 
intermediate forms; B, rapid increase of force (force jump) from 5pN to 25N reveals the 
unfolding process, in which the fragment unfolded in steps of 11, 10, and 4 helical turns. 
  
132 
Table 6. Strains and plasmids used in this study 
 
Strain or Plasmid Description 
Strains  
BL21* pET21aβhelix 
(R1/CR3) BL21* transformed with pET21aβhelix (R1/CR3) 
BL21* pET21aMCD BL21* transformed with pET21aMCD 
BL21* pET21aR1 BL21* transformed with pET21aR1 
BL21* pET21aCR3 BL21* transformed with pET21aCR3 
BL21* pET21aR2 BL21* transformed with pET21aR2 
pET21aβhelix (R1/CR3) 
Sequences encoding codons 777-1256 of fhaB 
cloned into pET21a and includes sequences for a 
Cys residue at the N-terminus 
pET21aMCD 
Sequences encoding codons 1479-1954 of fhaB 
cloned into pET21a and includes sequences for a 
Cys residue at the N-terminus 
pET21aR1 
Sequences encoding codons 323-830 of fhaB cloned 
into pET21a and includes sequences for a Cys 
residue at the N-terminus 
pET21aCR3 
Sequences encoding codons 1117-1612 of fhaB 
cloned into pET21a and includes sequences for a 
Cys residue at the N-terminus 
pET21aR2 
Sequences encoding codons 1480-1980 of fhaB 
cloned into pET21a and includes sequences for a 
Cys residue at the N-terminus 
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